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Introduction
Diabetes mellitus is defined by chronically increased blood glucose levels, e.g.,
‘hyperglycemia’, and is classified into two major diseases: type 1 and type 2. Type 1
diabetes is defined as the absolute deficiency of insulin secretion and the absence
of C-peptide, and type 2 diabetes as the combination of resistance to insulin action
and an inadequate compensatory insulin secretory response of the pancreatic beta-
cell.1, 2 Diabetes mellitus affects approximately 5% of the general population. Type
2 diabetes accounts for about 85-90% of all patients with diabetes mellitus.3 
The prevalence of patients with type 2 diabetes mellitus increases rapidly and will
be doubled worldwide in 2010 compared to 1999. In the Netherlands, a prevalence
of diabetes mellitus of 8.3% was found in a population of 50-74 year old subjects4;
the overall prevalence of patients with type 2 diabetes is currently approximately
300,000 and is expected to increase to 400,000 – 500,000 by 2010.5 
Figure 1.1 The metabolic syndrome; genes and environment interacting
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Changes in lifestyle such as decreased physical activity, increasing obesity and
changes in food consumption, and ageing of the population have been implicated
in this epidemic.6 These unfavorable lifestyle habits accompanied by a higher risk
for the development of insulin resistance and type 2 diabetes is also referred to as
‘diabesity’ (Figure 1.1). 
Figure 1.2 Risk of cardiovascular events in diabetics versus non-diabetics aged 
45-74 years. Adapted from the Framingham Study.13
Patients with type 2 diabetes have an increased risk of morbidity and
mortality from microvascular (retinopathy, neuropathy, nephropathy) and
macrovascular (myocardial infarction, stroke, and peripheral vascular disease)
complications.7, 8 Patients with type 2 diabetes have a two- to fourfold increase in
cardiovascular risk and 80% of them will eventually develop cardiovascular disease
(Figure 1.2).9-13 Part of the increased risk may be explained by the observation that
type 2 diabetes mellitus clusters with several other cardiovascular risk factors.14-16
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the Insulin Resistance Syndrome (IRS) or metabolic syndrome, including insulin
resistance, hyperglycemia, obesity, dyslipidemia, and hypertension.14, 17 
The pathogenesis of type 2 diabetes mellitus is thought to involve an
interaction of environmental factors with genetic susceptibility (Figure 1.1).18, 19 In
patients with type 2 diabetes and established fasting hyperglycemia, the rate of
basal hepatic glucose production is excessive, despite plasma insulin secretions that
are increased. Furthermore, defects in insulin receptor function, insulin receptor-
signal transduction pathway, glucose transport and phosphorylation, glycogen
synthesis, and glucose oxidation contribute to muscle insulin resistance.20 Impaired
insulin secretion also plays a major role in the pathogenesis of glucose intolerance
in patients with type 2 diabetes.1 Although debate still continues about which
defect – insulin resistance or impaired insulin secretion – initiates the cascade of
events leading to overt diabetes mellitus, patients with type 2 diabetes mellitus
eventually are characterized by defects in both insulin secretion and insulin
action.21
The importance of glycemic control in type 2 diabetes mellitus
Aggressive management of hyperglycemia aims to reduce microvascular and/or
macrovascular complications in patients with type 2 diabetes. More definitive
information on the relation between improved glycemic control and prevention of
complications was recently provided by the United Kingdom Prospective Diabetes
Study (UKPDS).22-25 The main purpose of this randomized clinical trial was to
investigate whether intensive treatment to control glucose levels in people with
newly diagnosed type 2 diabetes is effective in reducing the incidence of clinical
complications in a study lasting 20 years. The median follow-up was 10.0 years;
during this period a difference in HbA1c values of 0.9 percentage points (7.0%
compared with 7.9%, p< 0.001) was maintained between the group assigned to
intensive therapy (sulfonylureas, insulin, or metformin) and the group assigned to
conventional therapy (diet). 
The main conclusions of the study were that intensive glucose lowering treatment
reduced diabetes-related events (p= 0.03), mainly as a consequence of improved
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microvascular outcomes (background retinopathy in particular, p= 0.01). There
was however only a borderline significant risk reduction in myocardial infarction (-
16%, p= 0.052) and no effect on diabetes-related mortality or all-cause mortality in
the group receiving intensive treatment.24 
Results from several other studies have similarly raised the possibility that
treatment with agents that increase insulin levels (i.e. sulfonylureas and exogenous
insulin) may actually be detrimental.26-29 Treatments that are effective in lowering
glucose levels can have simultaneous effects on other cardiovascular disease risk
factors and should be considered when identifying appropriate therapy for
individual patients. Sulfonylureas and insulin may cause weight gain and
hypoglycemia, but insulin treatment has been shown to improve lipid abnormalities
in people with type 2 diabetes. 
Metformin can be considered an effective treatment to improve glycemic
control in obese type 2 diabetic patients30, 31 and has a beneficial effect on the
diabetic lipid profile that is particularly characterized by low high-density
lipoprotein (HDL)-cholesterol concentrations and hypertriglyceridemia.32, 33 
Switching therapies in type 2 diabetes patients: a ‘normal’ course
of events?
The UKPDS showed that type 2 diabetes mellitus is a chronic progressive disorder
(Figure 1.3).22, 24, 25 After an initial and similar decrease in the HbA1c value with
metformin, sulfonylureas, or insulin, the rate of increase in this level was identical
to that in the group treated with diet therapy. This important observation
emphasizes the need for constant reassessment of the diabetic patient and
appropriate adjustment of the therapeutic regimen in order to maintain the desired
level of glycemic control.22 
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Figure 1.3 Type 2 diabetes mellitus is a progressive disease: beta-cell function deteriorated 
to 28% in UKPDS diet-treated patients (adapted from the UK Prospective
Diabetes Study Group. Diabetes 1995; 44:1249-1248)
Type 2 diabetes generally affects older people in whom the side effects of
improved glycemic control may be less acceptable. On the basis of the results
reviewed above, it seems most prudent to reduce blood glucose in patients with
type 2 diabetes to levels as close to normal as possible while avoiding symptomatic
hypoglycemia. Effective treatment will require the combined use of diet, exercise,
oral agents, and insulin.22 
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Stepwise treatment of type 2 diabetes
The treatment of type 2 diabetes mellitus includes a number of sequential steps to
lower hyperglycemia. These comprise the cornerstone of treatment of type 2
diabetic patients.
According to the Dutch and international guidelines, target levels of glycemic
control (capillary whole blood) are as follows34-36:
Good Acceptable Poor
Fasting glucose (mmol/l) 4-7 7-8 > 8
HbA1c (%) < 7 7-8.5 > 8.5
Step 1: Lifestyle recommendations, referral to dietician, after three months checking
of blood glucose values.
Step 2: After dietary failure, initiate pharmacologic treatment with a sulfonylurea
derivative (for instance tolbutamide 500 mg once daily) in patients having a BMI <
27 kg/m2 and with metformin (500 mg once daily) in obese patients (BMI > 27
kg/m2). Start with the lowest dose, increase every 2-4 weeks until target values are
achieved.
Step 3: If step 2 fails, add metformin or sulfonylurea, respectively. If a patient has
contra-indications or suffers from unpleasant side effects: replace the relevant
agent with acarbose (50 mg three times daily). Combination therapy of three or
even more agents is not recommended.
Eventually, in diabetic patients in whom glycemic control is not achieved
with maximal combined oral agent therapy, several options are available37: addition
of bedtime insulin in combination with oral treatment, switching to a mixed-split
insulin regimen, or addition of a third oral agent. If oral treatment fails (secondary
failure), addition of or switching to insulin is the final therapeutic option. Self-
monitoring of blood glucose takes an important place in this treatment strategy. 
According to the Dutch guidelines for type 2 diabetes mellitus patients, 3-
monthly and yearly check-ups are recommended. Fasting blood glucose (patients
on diet or users of oral hypoglycemic agents) or a glucose curve (users of insulin)
Introduction
17
are advised to be determined at the 3-monthly check, whereas blood pressure,
fasting blood glucose, HbA1c, creatinin, total cholesterol, HDL-cholesterol, and
triglycerides are recommended to be performed at the yearly check. Diet and
exercise must be emphasized even after pharmacological treatment has begun.
Insulin therapy in the primary care setting
It is important to recognize that, ultimately, most patients with type 2 diabetes will
require treatment with insulin, either alone or in combination with an oral agent to
achieve sufficient glycemic control.38 Numerous studies have shown that excellent
glycemic control can be achieved with intensive insulin therapy in patients with
type 2 diabetes.38, 39 Recently, Dandona et al suggested even an anti-inflammatory
and potential anti-atherogenic effect of insulin.40 These research results suggested
there should be little hesitation about using insulin either alone or in combination
with oral agents if glycemic control cannot be attained with oral agents alone.41-43 
However, most studies of intensive insulin therapy have been carried out in
academic settings, using strict (research) protocols with specialty teams devoted to
patient care. For instance, Goddijn studied prospectively a cohort of patients
referred by general practitioners to an outpatient department for consideration of
insulin therapy.44 In contrast, most primary care physicians do not have specialized
training in insulin use and management of its complications, do not have sufficient
time to follow up patients at frequent intervals to ensure appropriate adjustment of
the insulin dose, and do not have diabetes specialty teams to assist them.
Moreover, the diabetes mellitus guidelines of the Dutch College of General
Practitioners provide no clear indication when insulin should be given or when a
patient should be referred to a specialist.34
Hayword and coworkers examined insulin therapy prescribed by general
practitioners in a large staff-model health maintenance organization.45 In 1738
insulin-treated patients with type 2 diabetes the mean decrease in HbA1c value was
0.9 percentage points, and 60% of patients had a HbA1c  value that exceeded 8.0%
at 2 years. In a parallel cohort, 43% of patients who were taking sulfonylureas had
an HbA1c value that exceeded 8.0%. One can raise criticisms about this study, but
the results do not indicate any superiority of insulin over sulfonylureas or vice
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versa in a primary care setting. Although performed in a randomized clinical trial
setting, the UKPDS also failed to show any advantage of insulin over oral agents.24,
25
The general practitioner (GP): a key agent in the dynamics of type 2
diabetes mellitus care
Standards of care for diabetes have been widely disseminated since the late 1980s36,
but primary care providers have been slow to adopt the recommended screening
and treatment guidelines. Yet, while there is an extensive literature on patients’
beliefs and attitudes that affect adherence to recommended treatment regimens,
little is known, by comparison, about GP beliefs and attitudes that may interfere
with their adherence to current standards of care. In a study by Larme and Pugh
on barriers to guideline implementation, GPs rated diabetes as significantly harder
to treat than hypertension and angina pectoris. 46 Explanations for frustrations with
diabetes care include the characteristics of the disease itself and the complexity of
its management, and a perceived lack of support from society and the health care
system for their efforts to control diabetes. 46, 47
In particular, physicians are weary of treading the fine line between tight
control and hypoglycemia. Furthermore, diabetes is harder for GPs to treat than
other chronic conditions because its successful management relies to a great extent
on lifestyle change, which is largely beyond GP’s control. 48 Diabetes treatment is
also difficult because although GPs may feel considerable urgency to control
diabetes, their patients do not and still think of type 2 diabetes as a ‘mild’ disease.
In the evaluation of the quality of care the concepts of efficacy and effectiveness
are important. Efficacy is the achieved optimal effect under ideal circumstances
(randomized clinical trials, experiments) and effectiveness is the maximal attainable
effect under everyday circumstances (routine practice). There are several factors
explaining the gap between research and practice. Achieving good diabetic control
is affected by the doctor’s attitude and practices and by the patient’s understanding
of the disease and the extent to which they will alter their lifestyle in the quest for
good blood glucose control. Therefore, both doctor and patient can contribute to
increase the effectiveness of diabetes care. In addition, several pharmaceutical care
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interventions may help to improve the effectiveness of diabetes care in general 49-52,
and cardiovascular risk management in particular.53, 54 
UDES framework
The Utrecht Diabetes Epidemiology Studies (UDES) were initiated to study the
effectiveness of diabetes care and drug therapy outcomes in diabetes (i.e. glycemic
control, micro- and macrovascular complications), to evaluate the management of
risk factors (i.e. cardiovascular disease, pregnancy, psychiatric disorders, poor
compliance), and to investigate innovation in diabetes therapy. For the studies, a
database comprising pharmacy, hospital admission and general practitioner data
was established to gain more insight in the treatment of diabetes mellitus in daily
clinical practice. 
Evidence of a drug’s efficacy from randomized controlled clinical trials is
often obtained in selected patient groups who typically have less comorbidity than
the patients who receive these drugs in clinical practice.55, 56 More insight in the
effectiveness of treatment of type 2 diabetes mellitus patients in actual daily
practice and the possible extrapolation of artificial trial results may be obtained by
using data that are routinely collected in primary care and community pharmacies.
As type 2 diabetes commonly coexists with concomitant diseases and risk factors,
polypharmacy is often indicated. Optimal pharmacotherapy of these diseases and
risk factors is more complicated than the treatment of these conditions without the
presence of other diseases.57 Therefore, observational studies have the advantage
to provide us with information about longitudinal effects of treatment. 
Moreover, because type 2 diabetes is a chronic, incurable and progressive
disorder, constant reassessment of glycemic control and treatment regimen is
needed. Switching between therapeutic options (life style intervention, start of oral
drug treatment, increasing doses and eventually changeover to insulin) takes an
important position in optimizing the treatment of the patient with type 2 diabetes
mellitus.
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Outline of the thesis
As outlined in the text above, treatment of type 2 diabetes is (still) far from ideal.
Practitioners are in the middle of making constantly decisions having on one hand
extensive treatment guidelines, recommendations, et cetera (mostly based on more
or less artificial trial results) and on the other hand a care and treatment demanding
patient. It is even more complicated, the person by that hand is frequently not
feeling or perceiving him/her self as a patient, but because some ‘tests’ say he or
she is, something has to be done. 
And current medical evidence says something needs to be done otherwise
the risk of both micro- and macrovascular complications will be high. Studying
determinants of glucose lowering drug use and their effects may help to explore
the gap between clinical practice and evidence (as recommended in guidelines and
standards for care of type 2 diabetes). In this thesis, we will meet each other in a
number of studies where the treatment of type 2 diabetes mellitus has been
assessed with regard to determinants and effects of the hub-and-spoke switching
between the individual glucose lowering treatment strategies. The results of these
studies will quantify the influence of patient characteristics on changes in glucose
lowering treatment strategies. Based on these outcomes a GP can improve the
prognosis of her/his diabetic patients by pushing forward the implementation of
necessary changes in the individual treatment strategy.
We defined two relevant outcomes in the course of type 2 diabetes treatment
strategy:
1. Start of oral drug therapy following life style intervention (diet, exercise);
2. Switch to insulin therapy.
Intermediate changes in glucose lowering therapy were also examined, like
intensification of oral drug therapy by increasing doses or combining drugs.
The specific study aims were:
Start of oral hypoglycemic therapy in type 2 diabetes
To investigate determinants of starting oral glucose lowering drug use in
newly diagnosed patients in daily practice (Chapter 2).
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Determinants and effects of different strategies in type 2 diabetes therapy
To assess whether more intensive glucose lowering therapy results in
adequate glycemic control and if more severe diabetes is associated with more
advanced cardiovascular disease or intensified cardiovascular treatment (Chapter 3).
To determine the effects of cardiovascular drug treatment and blood
pressure levels on glycemic control (Chapter 4).
Switching to insulin therapy: determinants and consequences
To investigate which factors are associated with switching from oral
hypoglycemic agents to insulin therapy in general practice (Chapter 5).
To assess whether switching to insulin is associated with medication refill
compliance of oral hypoglycemic agents (Chapter 6).
To study the relationship between use of antipsychotic drugs and switching
to insulin therapy  (Chapter 7).
Finally, several type 2 diabetes treatment strategies and suggestions for further
research are discussed in Chapter 8. 
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CHAPTER 2
Initiation of Glucose Lowering
Therapy in Type 2 Diabetes Mellitus
Patients in General Practice
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Abstract
Aim - Purpose of this study was to investigate determinants for the initiation of
glucose lowering therapy in general practice and perspectives of these type 2
diabetes mellitus patients with respect to future glycemic control.
Methods - Among incident type 2 diabetic patients in general practice factors
associated with initiation of glucose lowering therapy were examined by Cox’
regression analyses. Also the relationship between glucose levels at diagnosis and
future glycemic control was investigated.
Results - In total, 603 newly diagnosed patients with type 2 diabetes mellitus were
included in the study. Of the incident type 2 patients, 319 (53%) started
immediately (in the first month following diagnosis) with oral therapy. One, two,
and three years after diagnosis of diabetes the cumulative incidences were 71%
(CI95%: 66-73%), 75% (CI95%: 71-79%), and 81% (CI95%: 77-84%), respectively. Age,
body weight, systolic and diastolic blood pressure, history of cardiovascular
disease, or total serum cholesterol values were not associated with time to start of
oral drug therapy. Level of hyperglycemia at diagnosis was strongly related to
initiation of drug therapy and future glycemic control.
Conclusion - This study shows that the initial severity of diabetes, assessed by the
degree of hyperglycemia at the time of diagnosis, is a major factor in determining
the time to start of pharmacological treatment of diabetes and the likelihood of
achieving target levels of glycemic control in the future, independent of glucose
lowering strategy. 
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Introduction
Glycemic control is the cornerstone of the management of type 2 diabetes mellitus.
Lifestyle intervention (i.e. proper nutrition, physical exercise) is the first treatment
step in patients with only moderate hyperglycemia. Although difficult to achieve,
modest weight loss and increased exercise have beneficial effects on glucose values,
lipids and blood pressure.1-4 In the United Kingdom Prospective Diabetes Study
(UKPDS), newly diagnosed adults with type 2 diabetes reduced their average
HbA1c level from ~9 to 7% after three months of dietary treatment.1, 5  When
despite implementation of these lifestyle changes the fasting blood glucose target
(< 8.0 mmol/l) is not achieved within three months, drug treatment should be
considered.6, 7
In the UKPDS, glycemic control deteriorated gradually with time, even in
the intensively treated patients.5 This worsening of glycemic control has been
attributed to the natural course of type 2 diabetes and lack of efficacy of current
hypoglycemic therapy.5, 8 Recent studies show that early addition of insulin or
metformin can significantly improve glycemic control without leading to increased
hypoglycemia or weight gain.1, 8 
However, little is known about the efficacy of treatment of type 2 diabetes
patients in daily primary care. Especially, the extent and effectiveness of lifestyle
interventions (dietary treatment, increased exercise level) in routine care remains
unclear. For instance, in some cases doctors decide to start drug therapy
immediately following diagnosis. There is little data on the clinical grounds (patient
characteristics) on which general practitioners (GPs) make this decision and the
perspectives of these patients with respect to future glycemic control.
The aim of this study was to investigate determinants for the initiation of
oral glucose lowering therapy in newly diagnosed type 2 diabetes mellitus patients
in general practice.
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Patients and Methods
Study setting
This study was performed among patients who received comprehensive primary
care from 17 GPs in a Dutch middle-sized town (n=50,574). Detailed clinical
information was captured in a single electronic medical record system
(Medicom®), whereas information on pharmacy based drug dispensings was
registered in a second database (Pharmacom®). Hospital admission and discharge
data were available through the PHARMO Record Linkage System.9, 10 The
following data were available for this study: demographic data, medical history,
comorbidity (including International Classification of  Primary Care (ICPC) codes),
diabetic complications, prescriptions and drug dispensings, doctor in attendance
(specialist, GP), referrals to specialists, and a ‘medical journal’ (a database-file
containing free text, as recorded by the GP in the computer).
To guarantee privacy, all analyses were performed using anonymous records.
Regarding medication prescriptions and dispensings, all drugs were coded
according to the Anatomical Therapeutic Chemical (ATC) Classification. Hospital
diagnoses were coded according to the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM codes).
Subjects
In the Netherlands, most patients with diabetes mellitus type 2 visit their GP for
regular check-ups. They were identified from the registries by International
Classification of Primary Care (ICPC-2) codes T90 or T90.2, and/or the description
‘diabetes mellitus type 2’ in their medical records. Data from both primary care and
the pharmacy based dispensing records were complete for the period of February
1994 to August 2000 and were considered for the present study. 
For the present study we selected all newly diagnosed patients with type 2 diabetes
during this period (N=603). Following the Dutch General Practitioners’
Guidelines, treatment of newly diagnosed patients starts with dietary advice and
encouragement of physical activity.7 Oral glucose lowering medication is indicated
if target levels of blood glucose are not achieved within 3 months. Drugs of first
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choice are sulfonylurea derivatives and, in obese patients (body mass index > 27),
metformin. Glycemic control was defined in terms of poor (HbA1c > 8.5%),
acceptable (HbA1c: 7.0-8.5%), and good control (HbA1c< 7.0%) according to the
College of Dutch General Practitioners’ Guidelines.7
Data analysis
For categorical variables, numbers and percentages and for continuous data means
and standard deviations (SD) or standard errors of the mean (± s.e.m.) were
calculated. For comparison of continuous variables and categorical variables, we
used the Students’ t-test and chi-square test, respectively. The Kaplan-Meier
method was used to calculate the cumulative incidence of glucose lowering drug
use, defined as: 1 – cumulative survival probability; under the assumption that
treatment will be continuous and lifelong after initiation of this medical therapy.
We performed log rank tests to assess differences between subgroups. 
We compared time to start of oral hypoglycemic drug treatment between four
strata of fasting and non-fasting blood glucose levels at diagnosis (FBG and
NFBG), defined by quartile cut-off points. Spearman’s correlation coefficient was
calculated to study the association between FBG and NFBG levels. 
Furthermore, we used Cox’ proportional hazards analyses and controlled for
confounding by including covariates (like age, gender, body weight and blood
pressure) in the model. We calculated hazard ratios (HR) with corresponding 95%
confidence intervals (CI95%). Start of oral hypoglycemic therapy was the event of
interest, date of censoring was the end of follow-up (death, migration, end of study
in August 2000).
With respect to glycemic control, mean differences between FBG and
NFBG strata were analyzed using analysis of variance (ANOVA). Additional
adjustments for potential confounders (age, gender, duration of diabetes, and body
weight) were made by including these as covariates. All analyses were carried out
using the statistical package SPSS version 9.0 for Windows.
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Table 2.1 General characteristics of newly diagnosed patients with type 2 DM (N=603)
Characteristic Mean (SD)  or % Total number of patients
Age at onset (years) 62.0 (13.5) 603 (100%)
Male (%) 43.4 262
Diabetes duration* (years) 3.0 (1.9) 603 (100%)
HbA1c (%) 7.6 (1.5) 317 (53%)
Weight (kg) 83.8 (17.8) 303 (50%)
Body Mass Index (kg/m2) 28.9 (5.2) 147 (24%)
Fasting blood glucose (mmol/l) 8.7 (2.5) 444 (74%)
Random blood glucose (mmol/l) 10.7 (3.8) 445 (74%)
Systolic blood pressure (mmHg) 150.7 (20.6) 407 (67%)
Diastolic blood pressure (mmHg) 86.4 (10.5) 405 (67%)
Total serum cholesterol (mmol/l) 5.7 (1.0) 373 (62%)
HDL cholesterol (mmol/l) 1.20 (0.31) 265 (44%)
Ratio HDL/ Total cholesterol 5.2 (1.5) 249 (41%)
LDL cholesterol (mmol/l) 3.60 (0.95) 178 (30%)
Triglycerides (mmol/l) 2.54 (2.34) 265 (44%)
Serum creatinine (mmol/l) 84.1 (23.0) 369 (61%)
History of cardiovascular disease (%) 21.2   127
Ischemic heart disease (excl. MI) 11.3 68
Myocardial infarction 7.1 43
Heart failure 3.6 22
CVA, TIA 7.0 42
Switchers to insulin therapy (%) 10.9 66
Values are proportions or means, standard deviation (SD) between parentheses
* At date of end of study (August 31st 2000) or date of censoring (loss to follow up)
CVA: cerebrovascular accident; HbA1c: glycosylated hemoglobin; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; MI: myocardial infarction; TIA: transient
ischemic attack 
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Results
Table 2.1 shows the general characteristics of the 603 newly diagnosed patients
included in this study. Regarding metabolic measurements, such as fasting blood
glucose and cholesterol measurements, mean values during diabetes are given. In
total, 136 patients (23%) remained on dietary treatment only (mean duration of
diabetes: 2.1±0.1 years) and 66 (11%) patients switched to insulin therapy after a
mean diabetes duration of 1.6±0.2 years. The overall prevalence of (recorded)
cardiovascular disease was higher in men compared to women (age-adjusted OR
2.0, CI95%: 1.3-3.0). 
A history of ischemic heart disease in general (ORadj 2.4, CI95%: 1.4-3.9), and
especially myocardial infarction (ORadj 3.9, CI95%: 1.9-7.8), was more common in
males, while females more often suffered from heart failure (ORadj 2.5, CI95%: 0.9-
8.3).
Figure 2.1 Start of oral hypoglycemic agent (OHA) use after diagnosis of diabetes
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Start of oral hypoglycemic therapy in newly diagnosed patients
Figure 2.1 represents the cumulative incidence (Kaplan Meier curve estimate) of
glucose lowering drug use in newly diagnosed type 2 diabetes mellitus patients. Of
the incident type 2 patients, 319 (53%) started immediately (in the first month
following diagnosis) with oral therapy. One, two, and three years after diagnosis of
diabetes the cumulative incidences were 71% (CI95%: 66-73%), 75% (CI95%: 71-
79%), and 81% (CI95%: 77-84%), respectively. The curves show that men started
with drug treatment sooner after diagnosis, but this difference was not statistically
significant (logrank test statistic: 1.93, p= 0.17).  Indeed, 3 years after diagnosis
21% of women and 15% of men were still on dietary treatment only. Patients
treated with diet only were slightly more likely to be female than patients who
started drug therapy, e.g., 63% versus 55% women, respectively (p= 0.07).
Age, body weight (sex-adjusted), systolic and diastolic blood pressure,
history of cardiovascular disease, or total serum cholesterol values were not
associated with time to start of oral drug therapy. Furthermore, we compared time
to treatment in patients diagnosed before 1999 and since 1999, (introduction of
revised guidelines: recommended period to attempt reaching acceptable glycemic
control with dietary treatment only reduced to three months instead of six
months), but no difference was found.
In more than half of the patients (51.8%), tolbutamide was the drug of first choice,
followed by a second-generation sulfonylurea (gliclazide, glibenclamide,
glimepiride, and glipizide; 30.4%), and metformin (18.2%). Patients who started
with metformin weighed significantly more than other patients (97.3±3.0 versus
83.1±1.4 kg, respectively (p< 0.001)), and were younger at onset of diabetes
(56.7±1.4 versus 62.9±0.6 years, respectively (p< 0.001)). Acarbose was prescribed
in only 10 patients (2.1%) and 13 patients (2.8%) started oral treatment with two
drugs simultaneously, predominantly a combination of metformin and a
sulfonylurea.
In 398 patients (66%) fasting and/or non-fasting blood glucose (FBG and
NFBG) at diagnosis was recorded in the medical file. Mean FBG and NFBG
values were 10.8 (SD 4.0) and 14.6 (5.8), respectively. In a subsample of patients
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with both measurements available, fasting and non-fasting blood glucose levels at
diagnosis (n=185) showed a moderate correlation (Spearman’s r=0.43, p<0.001). 
As shown in Figures 2.2a and 2.2b, initiation of hypoglycemic drug therapy was
strongly related to glucose level at diagnosis.
2.2 a Fasting blood glucose and
time to drug treatment
2.2 b Non-fasting blood glucose
and time to drug treatment
Figure 2.2 a and 2.2 Start of oral hypoglycemic therapy and glucose levels at diagnosis 
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Time to treatment increased from 0.2 (SD 0.6, FBG > 13.1 mmol/l) to 1.4 years
(1.5, FBG <  7.9 mmol/l); test for trend p< 0.001. In a Cox’ regression analysis,
adjusted for age at onset of diabetes and gender, this relationship remained
statistically significant; HRs were 1.7 (2nd quartile), 2.2 (3rd) and 2.9 (4th),
respectively, compared to the group with lowest FBG values. Patients starting
immediately with tablets to control their hyperglycemia had higher blood glucose
values at diagnosis compared to patients (N=136) who remained on dietary
treatment only; fasting blood glucose: 12.3±0.3 versus 8.9±0.4 mmol/l (p< 0.001),
non-fasting blood glucose: 16.6±0.5 versus 11.6±0.7 mmol/l (p< 0.001). 
Figure 2.3 shows the association between level of hyperglycemia at diagnosis,
according to quartiles of fasting blood glucose values, and future glycemic control
(most recent HbA1c measurement available, N=193). The association between
NFBG at diagnosis and actual glycemic control followed a similar pattern (data not
shown, N=177). Glycemic control differed significantly between groups, also after
adjustment for age and duration of diabetes (p= 0.016). The lowest quartile (1st
quartile: FBG < 7.9 mmol/l) had significantly better control than patients in the
3rd and 4th quartiles. The mean duration of diabetes at the time of this
measurement was 2.4 years and did not differ between quartiles. Patients who
remained on dietary treatment only had significantly lower HbA1c levels compared
to patients who started oral glucose therapy immediately following diagnosis and
patients who started oral therapy later; 0.6% points (CI95%: 0.2-1.0)  and 0.7%
points (CI95%: 0.2-1.2) lower, respectively (adjusted for age, gender and duration of
diabetes). 
In groups of patients with similar glucose levels at diagnosis (defined by
tertiles of FBG and NFBG levels), immediate initiation of glucose lowering
medication was not significantly related to future glycemic control. Only, in the
highest tertiles (FBG > 11.9 mmol/l and NFBG > 16.2 mmol/l respectively)
patients showed a tendency towards better future glycemic control when they
immediately started pharmacological treatment. In the highest tertile of FBG,
proportions of patients with good, fair and poor control respectively were 32%,
40%, 28% in the ‘immediate starters’ compared to 25%, 25%, 50% in the other
patients. 
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Initiation of insulin therapy was not related to glucose levels at diagnosis, but
among switchers to insulin the time to treatment with insulin shortened with
increasing blood glucose level, from 2.9 years (NFBG < 11.4 mmol/l) to 1.3 years
(NFBG > 16.2 mmol/l); test for trend, p= 0.05, adjusted for age and gender.
Patients who switched were younger at diagnosis, 57.8±1.7 versus 62.7±0.6 years
(p= 0.001) compared to non-switchers.
 
Figure 2.3 Glucose level at diagnosis and future glycemic control
Asterisks: p< 0.01, metabolic control compared to the first quartile 
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Discussion
We assessed determinants of initiation of pharmacological glucose lowering
treatment in newly diagnosed type 2 diabetes mellitus patients in general practice.
Fifty-three percent of the patients started immediately with blood glucose lowering
therapy. The strongest predictors of time to drug therapy were fasting and non-
fasting blood glucose levels at diagnosis. Also, a tendency to prescribe oral
hypoglycemic agents sooner in men than women was shown, although not
statistically significant. Furthermore, blood glucose levels at diagnosis of diabetes
predicted future glycemic control; patients in the lowest quartiles had significantly
lower future HbA1c levels, independent of actual glucose lowering therapy. 
In the United Kingdom Prospective Diabetes Study, level of hyperglycemia
at diagnosis was also associated with poorer prognosis: patients with high glucose
levels suffered from more subsequent cardiovascular disease, ischemic heart
disease in particular, retinopathy, erectile dysfunction, and showed progressive
requirement for multiple therapies.11, 12, 13 Furthermore, its known that
hyperglycemia is independently strongly related to higher mortality and
cardiovascular morbidity rates.14-19
Strength of this study is the use of routinely collected primary care data,
which reflect usual clinical care. General practice networks provide databases that
may fruitfully be used for research. The use of computerized databases permits
analyses of diagnostic, treatment and prescribing patterns in different patient
groups within the general population. These databases enhance access to health
related information of large groups of patients over a long period of time. 20, 21
From other studies, it is known that the sensitivity of general practice registries in
identifying patients with diagnosed diabetes exceeds 90%.22
Some limitations of this study need to be addressed. In only 66% (398/603)
of the patients a blood glucose value at diagnosis was recorded in their medical file.
Partly, this can be explained by the fact that a considerable proportion of type 2
diabetes mellitus patients is diagnosed by an accidental finding of increased glucose
level in routine laboratory examinations performed in hospitalized patients.
Furthermore, data on body weight and body mass index were scarce. The presence
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(or absence) of obesity is of great importance in the etiology and treatment
spectrum of type 2 diabetes.
Early in the course of the disease when insulin resistance and
hyperinsulinemia characterize diabetes, energy restriction not related to weight loss
and moderate weight loss (5-10% of body weight) have been shown to improve
hyperglycemia.23, 24 Moreover, intentional weight loss in overweight individuals
with type 2 diabetes is also associated with substantial reductions in mortality.25
While the disease progresses and insulin deficiency becomes the central issue, it
may be too late for weight loss to be helpful. According to the Dutch guidelines
for type 2 diabetes mellitus patients, pharmacological treatment has to be
considered if target levels of glycemic control are not achieved after a dietary
treatment period of at least three months.7 However, the results of this
observational study in general practice show that in about half of the patients with
type 2 diabetes GPs started drug treatment immediately following diagnosis.
Although patients who immediately started with hypoglycemic drugs had higher
glucose levels at diagnosis compared to the remaining subjects, GPs’ intentions to
deviate from the standard for diabetes care remain unclear. Maybe this reflects
doubts among GPs about the effectiveness of very time-consuming lifestyle
interventions in the majority of the patients. Furthermore, the presence (or
absence) of severe hyperglycemic symptoms in the individual patient is likely to
play an important role in making this decision. However, we did not take any
subjective measurements, like patients’ complaints, into account. Moreover, lack of
financial support and insufficient availability of dieticians  may also be important
issues. It is also possible that GPs are likely to register patients as having type 2
diabetes at the moment oral hypoglycemic therapy is started, leading to a certain
degree of selection bias.
One might expect hyperglycemia to be treated more aggressively in patients
with a worse cardiovascular profile or even established cardiovascular disease at
diagnosis of diabetes. However, we found time to start of oral glucose lowering
therapy not to be associated with a history of cardiovascular disease and
cardiovascular risk factors such as body weight, blood pressure, and total serum
cholesterol. Maybe there is still lack of awareness among GPs of the importance to
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treat diabetes as a multifactorial disease. On the other hand, current targets for
glycemia, lipids and blood pressure are attainable in only 50%-70% of individuals
with type 2 diabetes.26 
We were intrigued by the observation that a small proportion (about 17%
after 3 years of diabetes) of the patients remained on dietary treatment only for a
long time and nevertheless still achieved good glycemic control (HbA1c< 7.0%). In
the UKPDS those patients were termed ‘diet satisfactory’ and excluded from the
analysis after the 3-month run-in period. Of the initially 4,075 included newly
diagnosed type 2 diabetes patients, after 3 years 357 (11.5%) patients and even
after 9 years 115 (8.6%) patients maintained fasting plasma glucose levels < 6.0
mmol/l on diet only.11 The most likely explanation for this observation is that type
2 diabetes may be a curable disease in moderate obese patients who can achieve
sufficient weight loss.27-29  Alternatively, part of these patients may have been
incorrectly diagnosed as having type 2 diabetes mellitus.
In conclusion, this study shows that the initial severity of diabetes, assessed
by the degree of hyperglycemia at the time of diagnosis, is a major factor in
determining the time to start of pharmacological treatment of diabetes and the
likelihood of achieving target levels of glycemic control in the future, independent
of glucose lowering strategy. Furthermore, the findings indicate that more research
is needed on the patients who remain on diet only for a long time while achieving
good glycemic control.
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Abstract
Aim - Glucose lowering therapy in type 2 diabetes includes successive steps, but
little is known about control of hyperglycemia and cardiovascular risk factors in
daily practice when treatment is intensified. Aim of our study was to investigate
whether more intensive glucose lowering therapy results in adequate glycemic
control and if more severe diabetes is associated with more cardiovascular disease
and/or intensified cardiovascular drug treatment.
Methods - In a cross-sectional study, including patients with type 2 diabetes mellitus
in general practice, the association between glucose lowering treatment and the
occurrence of cardiovascular morbidity and treatment was examined by regression
analyses. Four modalities of glucose lowering therapy were compared: dietary
treatment only, sulfonylurea (SU) therapy only, metformin (with or without SU),
and insulin therapy. 
Results - In total, 1,072 patients with type 2 diabetes mellitus were included in the
study. In only 60-85% of these patients studied in routine primary care, relevant
metabolic measurements were available. Fasting plasma glucose and mean HbA1c
increased significantly with escalating glucose lowering therapy. The proportion of
patients with well-controlled diabetes decreased from 53% (diet only) to 10%
(insulin). The overall prevalences of hypertension and hypercholesterolemia were
66% and 71% respectively, among those who had recordings of blood pressure
(N=748) and lipid levels (N=647) available. While stepping up hypoglycemic
treatment, the prevalence of hypertension increased, and the level of diastolic and
systolic blood pressure remained stable. With respect to lipid metabolism and
cardiovascular events no notable differences were found between the treatment
groups, only the prevalence of heart failure was higher in insulin treated patients.
Conclusion - Increased intensity of glucose lowering therapy was significantly
associated with poorer glycemic control, higher body weight and increased
prevalence of hypertension. Despite deterioration of glycemic control with
intensified glucose lowering treatment, control of other metabolic risk factors such
as high blood pressure and cholesterol remained stable, probably due to increased
prescribing of cardiovascular drug therapy. 
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Introduction
People with type 2 diabetes mellitus have a two- to fourfold increased risk of dying
of heart disease, and the co-existence of classic risk factors (hypertension, elevated
serum cholesterol, and smoking) increases this risk substantially – probably to a
greater extent than in nondiabetic individuals.1-4 In the United Kingdom
Prospective Diabetes Study (UKPDS), glycemic control deteriorated progressively
over time, even in the intensively treated patients.5 This worsening of glycemic
control has been attributed to the natural course of type 2 diabetes and the
eventual lack of efficacy of current hypoglycemic therapy.6, 7 
Because epidemiological analyses showed a continuous association between
the risk of cardiovascular complications, mortality and level of glycemia in diabetes
mellitus patients, adequate glycemic control remains very important.8, 9 This is also
emphasized in current type 2 diabetes mellitus guidelines.10, 11 Glucose lowering
therapy currently follows four steps: diet, sulfonylurea derivatives or metformin,
combined oral therapy, and eventually insulin. Every next step is initiated when
glycemic control is no longer adequate, mostly due to worsening of the disease. If
diabetes mellitus is more severe, faster progression of treatment takes place.
Because the common aim of glucose lowering therapy is to control hyperglycemia,
blood glucose levels should not be different between treatment groups. 
It is not yet entirely clear if more severe type 2 diabetes is also related to an
increased cardiovascular risk. This would result in increased levels of lipids, blood
pressure, body mass index and preferably intensified treatment of cardiovascular
disease. However, in the clinical practice of primary care there is often hesitation to
intensify drug treatment.12, 13
The aim of this study was to investigate whether more intensive glucose
lowering therapy results in adequate glycemic control.  In addition, we examined if
more severe diabetes (assessed by glucose lowering treatment category) was
associated with an increased presence of cardiovascular disease or intensified
cardiovascular treatment.
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Methods
Study setting
This study was performed among patients who received comprehensive primary
care from 17 general practitioners (GPs) in a Dutch middle-sized town (n=50,574).
All GPs used a single electronic medical record system (Medicom®), which was
available for this study, as well as information on drug dispensings from the
pharmacist database (Pharmacom®). Hospital admission and discharge data were
available through the PHARMO Record Linkage System.14, 15 
The following data were available: demographic data, medical history,
comorbidity (including International Classification of  Primary Care (ICPC) codes),
diabetic complications, drug dispensings, prescribing doctor (specialist, GP),
referrals to specialists, and the medical record (a database-file containing free text,
as recorded by the GP).
To guarantee privacy, all analyses were performed using anonymous records.
Regarding medication prescriptions and dispensings, all drugs were coded
according to the Anatomical Therapeutic Chemical (ATC) Classification. Hospital
diagnoses were coded according to the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM).
Subjects
The total study population consists of all  cases with  type 2 diabetes mellitus as
cared for by the network of collaborating GPs (n=17) during 1992-2000 (n=1,144).
In the Netherlands, virtually all patients with diabetes mellitus type 2 visit their GP
for regular check-ups. Study subjects were identified from the registries by the use
of oral glucose lowering agents or International Classification of Primary Care (ICPC-2)
codes T90 or T90.2, and/or the description ‘diabetes mellitus type 2’ in their
medical records. Data from both primary care and the pharmacy based dispensing
records were complete for the period of February 1994 to August 2000 and were
available for the purpose of this study. Subjects in whom the diagnosis of type 2
diabetes remained uncertain, due to incomplete and missing data, were excluded
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(N=72).  In patients with diagnosed type 2 diabetes but unknown date of diagnosis
we relied on January 1990 as a reasonable estimate.
In the analyses the following four categories of glucose lowering therapy
were compared: dietary treatment only, sulfonylurea (SU) therapy only, metformin
(with or without SU), and insulin therapy (with or without combined oral therapy).
The diabetic treatment was defined at the time of the last available (i.e. most
recent) measurement of a variable of interest. Therefore, the treatment groups
comprise dynamic populations, due to therapeutic changes during course of the
disease the actual treatment depends on the moment of the variable measured.
Presence of cardiovascular morbidity and treatment was defined on basis of: blood
pressure, total serum cholesterol level, fasting plasma glucose, HbA1c, total
cholesterol/HDL ratio, and body weight. 
Hypertension was defined as systolic blood pressure > 140 mmHg (in
patients older than 60 years > 160 mmHg) and/or diastolic blood pressure > 90
mmHg10, 16, or treatment with antihypertensive drugs.  
We defined hypercholesterolemia as a total serum cholesterol > 5.0 mmol/l
in concordance with the Dutch guidelines10, 16, or use of lipid lowering drugs.
Blood pressure and cholesterol levels were considered controlled if these levels
were below the above mentioned cut-off points. 
Furthermore, we looked at the management of dyslipidemia, according to
the standards of medical care for patients with diabetes mellitus of the American
Diabetes Association.11 Optimal LDL cholesterol levels are < 2.60 mmol/l,
optimal HDL cholesterol levels are > 1.15 mmol/l in men and > 1.40 mmol/l in
women and desirable triglyceride levels are <1.7 mmol/l.11, 17 
Glycemic control was defined in terms of poor (HbA1c > 8.5%), acceptable
(HbA1c:7.0-8.5%), and good control (HbA1c < 7.0%) according to the College of
Dutch  General Practitioners’ guidelines.10 Cardiovascular morbidity included:
cerebrovascular disease (including cerebrovascular accidents and transient
ischaemic attacks, ICPC codes: K89-K91, ICD-9-CM codes: 430-438), myocardial
infarction (ICPC: K75, ICD-9-CM: 410), ischemic heart disease (ICPC: K74, K76,
ICD-9-CM: 411-414), and heart failure (ICPC: K77, ICD-9-CM: 428).
Hospitalization data were available from January 1992-July 1999, meaning that
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from July 1999 until August 2000 we relied on general practitioner’s data only to
assess the incidence of cardiovascular events. 
Data analysis
For categorical variables, numbers and percentages and for continuous variables
means and standard errors of the mean (s.e.m.) were calculated. For comparison of
continuous and categorical variables, we used the Students’ t-test and chi-square
test, respectively. The association between glucose lowering treatment and
cardiovascular risk factors was examined by regression analyses. Depending on the
type of outcome variable (continuous or dichotomous), we performed multiple
linear or logistic regression, respectively, to estimate regression coefficients and
odds ratios (OR) with corresponding 95% confidence intervals (CI). We controlled
for potential confounding by age, gender, duration of diabetes, co-morbidity and
co-medication. 
In the analyses the following four mutually exclusive categories of glucose
lowering therapy were compared: dietary treatment only, sulfonylurea (SU) therapy
only, metformin (with or without SU), and insulin therapy (with or without
combined oral therapy). All analyses were carried out using the statistical package
SPSS version 9.0 for Windows.
Results
In this primary care population (mean age of 61.6±0.4 years and 45% males), the
estimated prevalence of (diagnosed) type 2 diabetes mellitus patients was 2.3%
(1,144/50,574; CI95%: 2.1-2.4%).
Table 3.1 shows the general characteristics of the 1,072 patients included in this
study. Age at diagnosis of diabetes and duration of disease refer only to patients
(N=888) with known date of diagnosis. After imputation (see Methods section) of
the missing values with regard to date of diagnosis, the mean age at diagnosis
changed slightly to 60.9 ± 0.42 years with an average duration of diabetes of 6.3 ±
0.17 years (N=1,025, 95.6%).
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Table 3.1 General characteristics of patients with type 2 DM (N=1,072) 
Characteristic Mean or % Total number of patients
Age at onset (years) 61.0 ± 0.45 888 (82.8%)
Male (%) 44.1 ± 1.5 473/599
Diabetes duration* (years) 5.7 ± 0.19 888 (82.8%)
HbA1c (%) 7.9 ± 0.06 573 (53.5%)
Weight (kg) 82.2 ± 0.7 523 (48.8%)
Body Mass Index (kg/m2) 28.7 ± 0.36 212 (19.8%)
Fasting blood glucose (mmol/l) 8.8 ± 0.09 784 (73.1%)
Random blood glucose (mmol/l) 10.8 ± 0.13 808 (75.4%)
Systolic blood pressure (mmHg) 152.0 ± 0.73 755 (70.4%)
Diastolic blood pressure (mmHg) 86.1 ± 0.36 752 (70.1%)
Total serum cholesterol (mmol/l) 5.7 ± 0.04 646 (60.3%)
HDL cholesterol (mmol/l) 1.22 ± 0.02 450 (42.0%)
Total cholesterol/HDL ratio 5.1 ± 0.12 429 (40.0%)
LDL cholesterol (mmol/l) 3.61 ± 0.05 305 (28.5%)
Triglycerides (mmol/l) 2.36 ± 0.10 447 (41.7%)
Serum creatinine (mmol/l) 87.1 ± 1.12 652 (60.8%)
History of cardiovascular disease 27.8 ± 1.4 298/774
Ischaemic heart disease (excl. MI) 15.3 ± 1.1 164/908
Myocardial infarction 9.7 ± 0.9 104/968
Heart failure 5.9 ± 0.7 63/1009
CVA, TIA 10.4 ± 0.9 111/961
Values are proportions or means ± standard error of the mean (SEM)
* At date of end of study (August 31st 2000) or date of censoring (loss to follow up)
CVA: cerebrovascular accident; HbA1c: glycosylated hemoglobin; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; MI: myocardial infarction; TIA: transient
ischemic attack
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Figure 3.1 Glycemic control (expressed by HbA1c) according to category of glucose lowering
treatment
Definition of glycemic control:
Poor: HbA1c > 8.5% 
Acceptable: HbA1c between 7.0-8.5% 
Good: HbA1c < 7.0%
0%
20%
40%
60%
80%
100%
diet (N=88) SU (N=285) metformin (N=110) insulin (N=89)
Glucose lowering treatment
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After a mean duration of 5.7 years (Table 3.1), in total 241 (22.5%) patients
switched to insulin therapy, and 174 (16.2%) remained on dietary treatment only.
In total, 992 (92.5%) patients had at least one of the outcome variables recorded
during the study period (after a diagnosis of diabetes).
With respect to glycemic control (HbA1c, fasting -, or random blood
glucose), 934 (87.1%) patients had at least one measurement registered.  At least
one of the variables of the lipid spectrum (total cholesterol, HDL, LDL, or
triglycerides) was recorded in 647 (60.1%) patients. Among patients with
measurements available, 24%, 38%, 11% and 45% had optimal mean levels with
regard to total serum cholesterol, HDL cholesterol, LDL cholesterol and
triglycerides, respectively. No differences in (recorded) prevalence of
cardiovascular disease in general between both sexes were observed. History of
myocardial infarction was more frequent in males (OR 1.7, CI95%: 1.1-2.5), while
females more often suffered from heart failure (OR 2.7, CI95%: 1.5-4.8).
Glycemic control and body weight
Fasting plasma glucose increased significantly with type of glucose lowering
therapy (test for trend: p<0.001, Table 3.2). In the group treated with diet only, the
mean fasting plasma glucose was 7.6±0.3 mmol/l, while in the sulfonylurea,
metformin and insulin treated patients glucose levels were 0.8, 1.2, and 1.6 mmol/l
higher, respectively. Mean HbA1c levels also differed significantly between
treatment groups (Table 3.2). Figure 3.1 shows the glycemic control in the four
groups of glucose lowering treatment. For example, the proportion of patients
with well-controlled diabetes varied from 53% (dietary treatment) to 10% (insulin
therapy).
Patients on metformin and/or insulin therapy were more obese than
patients in both other groups, with both a mean body weight of about 85 kg,
compared to 80.3 kg in the patients on diet only, and 79.3 kg in sulfonylurea users.
This difference was more marked in males than females (Table 3.2); male patients
using metformin or insulin weighed about 10 kg more.
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Table 3.2 Metabolic and risk factors by category of glucose lowering treatment
Variable Diet SU Metformin Insulin P-value*
FBG (mmol/l) 7.6 ± 0.2 8.4 ± 0.2 8.8 ± 0.3 9.2 ± 0.3 <0.001
HbA1c (%) 7.1 ± 0.1 7.8 ± 0.1 8.0 ± 0.2 8.4 ± 0.2 <0.001
Total cholesterol (mmol/l) 5.7 ± 0.1 5.5 ± 0.1 5.6 ± 0.1 5.5 ± 0.1 0.441
Cholesterol/HDL ratio 5.1 ± 0.2 4.8 ± 0.1 4.9 ± 0.2 5.7 ± 0.9 0.223
Hypercholesterolaemia 71.5% 66.8% 76.7% 76.3% 0.157
Body weight ♀♀ (kg) 76.0 ± 1.9 75.1 ± 1.7 79.2 ± 1.9 78.1 ± 4.0 0.230
Body weight ♂♂ (kg) 85.2 ± 1.7 83.5 ± 1.4 93.6 ± 2.5 94.0 ± 3.5 <0.001
Diastolic BP (mmHg) 83.2 ± 0.9 84.2 ± 0.7 85.3 ± 0.8 83.8 ± 0.9 0.495
Systolic BP (mmHg) 148.9 ± 2.0 150.8 + 1.4 147.9 ± 1.7 152.5 ± 2.1 0.559
Hypertension 51.2% 64.0% 74.4% 72.3% <0.001
Values are proportions (%) or means ± standard error of the mean (SEM)
* Test for trend
BP: blood pressure; FBG: fasting blood glucose; HbA1c: glycosylated hemoglobin; HDL:
high-density lipoprotein; SU: sulfonylurea derivative
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Hypertension
The overall prevalence of hypertension was 66% (CI95%: 63-69%) among those
who had recordings of blood pressure available (N=748). When divided by the
total study population (denominator), the prevalence was 46% (CI95%: 43-49%).
Among these patients with high blood pressure, 13% used no medication, in 43%
the blood pressure was adequately controlled by antihypertensives, and 44% were
treated but poorly controlled. Type 2 diabetes mellitus patients with recordings
available more frequently had a history of cardiovascular disease (30% versus 22%,
p= 0.005) than those without registered blood pressure measurements. Diastolic
and systolic blood pressure levels were comparable in the treatment groups (Table
3.2), but hypertension was significantly related to type of glucose lowering therapy;
the adjusted OR (dietary treatment as reference category) was 1.6 (CI95%: 1.0-2.4) in
the sulfonylurea treated group, 2.8 (CI95%: 1.7-4.5) in the metformin group, and 2.2
(CI95%: 1.3-3.8) in the group on insulin therapy. Treatment with antihypertensive
drugs was more common in the metformin and insulin treated groups compared to
the SU and diet treated groups (Figure 3.2), also after adjustment for body weight
and age.
Hypercholesterolemia
About 60% of type 2 diabetes mellitus patients had recordings of total cholesterol
in their medical record, among these 646 patients the prevalence of
hypercholesterolemia was 71% (CI95%: 67-74%). Total serum cholesterol values
were more likely to be available for male (p= 0.04) patients with a younger age at
onset of disease (p= 0.02). The proportions of these patients treated with lipid
lowering drugs are shown per glucose lowering treatment category in Figure 3.2.
With respect to the different types of glucose lowering treatment the prevalence of
hypercholesterolemia varied between 67% (sulfonylurea treatment) and 77%
(metformin). The proportion of patients with known total cholesterol values who
were treated with lipid lowering agents was 14% (CI95%: 12-17%).
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Cardiovascular morbidity and events
Type 2 diabetes mellitus patients on insulin therapy suffered more often from
cardiovascular disease compared to dietary and orally treated patients, 35% versus
25% and 26% in both other groups, respectively (OR compared to diet: 1.6, CI95%:
1.0-2.5). 
Figure 3.2 Treatment of cardiovascular risk factors in four strata of glucose lowering therapy 
Cardiovascular drugs are defined as: antithrombotics, cardiacs, diuretics, beta-blockers, ACE
inhibitors, calcium channel blockers, other antihypertensive drugs (mainly alpha-blockers), and
lipid lowering agents (ATC codes B01, C01-C03, C07-C10)
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After adjustment for age at diagnosis, duration of disease and gender, this
association was no longer significant (OR 1.4, CI95%: 0.8-2.3). When we compared
the prevalence of ischemic heart disease, myocardial infarction, cerebrovascular
disease, and heart failure separately between the treatment groups, only the
presence of heart failure (12%) was significantly higher in insulin treated patients
(ORadj 3.6, CI95%: 1.3-9.6). Treatment with any cardiovascular drug was more
common in groups treated with metformin and insulin compared to the
sulfonylurea and diet treated groups (see also Figure 3.2).
Discussion
In this study we compared metabolic and cardiovascular risk factors and the
presence of cardiovascular disease in type 2 diabetes patients according to different
glucose lowering treatment regimens: diet only, oral therapy (sulfonylurea and/or
metformin) and insulin therapy.
Significant differences across glucose lowering treatment groups were
observed for glycemic control (mean fasting glucose and HbA1c), body weight
(especially in males) and prevalence of hypertension. With respect to lipid
metabolism (total serum cholesterol and prevalence of hypercholesterolemia) and
cardiovascular events no notable differences were found, only the prevalence of
heart failure was higher in insulin treated patients. Treatment with antihypertensive
drugs, lipid lowering drugs and cardiovascular drugs was more common in
metformin and insulin treated patients compared to sulfonylurea and diet treated
patients.
The strength of this study is the use of routinely collected primary care data,
which reflect usual clinical practice. Computerized general practice networks
provide databases that may fruitfully be used for research, and permit analysis of
diagnostic, treatment and prescribing patterns in different patient groups within
the population at large. These databases enhance access to health related
information of large groups of patients over a long period of time.18, 19 From other
studies, it is known that the sensitivity of general practice registries in identifying
patients with diagnosed diabetes exceeds 90%.20 As patients with type 2 diabetes in
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the Netherlands are often cared for exclusively in general practice, comprehensive
data are more likely to be obtained from primary care than from hospital care.21 
In the Netherlands, the prevalence of type 2 diabetes in the age-group 30-74 years
is 2.7-3.2% and increases with age (7-8% per year)22, and the estimated prevalence
of 2.3% observed in the present study seems a representative and reliable
estimate.23, 24
To appreciate the results some aspects of this study need to be addressed.
According to the Dutch guidelines for type 2 diabetes mellitus patients, 3-monthly
and yearly checks are recommended in type 2 diabetes mellitus patients.10 Fasting
blood glucose levels (patients on diet or users of oral drugs) or glucose daycurves
(users of insulin) are advised to be determined at the 3-monthly check, whereas
blood pressure, HbA1c, creatinin, total cholesterol, HDL-cholesterol, triglycerides
are recommended to be performed at the annual visit. Our study disclosed
deficiencies in the general practitioners’ information system with regard to several
metabolic parameters and anthropometric measurements. In only 60-85% of these
primary care patients, relevant metabolic measurements were available. 
The substantial lack of cholesterol (40%) and glycemic control recordings
(13%) may be partly explained by the fact that patients were referred to the
laboratory and that measurements were carried out, but not recorded in the
medical file of the patients. This finding is consistent with other studies
performed in general practice.25, 26 Furthermore, general practitioners may have
written down measurements only when they varied from normal ranges. This
could have led to an overestimation of the number of uncontrolled type 2 diabetes
mellitus patients. Therefore it seems that the recorded data were insufficient for
optimal care of diabetes patients.
Data on body mass index were also fairly incomplete, largely because height
was seldom measured, despite regular weighing. In spite of the incompleteness of
the recorded data, our results with regard to level of blood pressure, lipid
measurements and glycemic control were equal to a recently performed Dutch trial
in general practice27 and observational studies by Harris and Grant et al.13, 28 
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As shown in The Utrecht Diabetes Project29, standardized data transfer between
GP, diabetologist and laboratory might offer an effective infrastructure for shared
diabetes care. 
Furthermore, in this study while stepping up the glycemic control,
simultaneously the treatment of other cardiovascular risk factors was intensified
(Figure 3.2) with progression of diabetes. While the prevalence of hypertension was
significantly higher in more intensively treated patients, levels of diastolic and
systolic blood pressure were comparable in the different treatment groups. It is
important to mention that due to confounding by indication the metformin treated
patients are more obese and therefore comprise high (cardiovascular-) risk
patients.10 In less obese patients, a sulfonylurea is first choice medication, followed
by addition of metformin and eventually insulin therapy.10
Glycemic control is important in the management of type 2 diabetes and
prevention of both micro- and macrovascular complications. Epidemiological
analysis of the UKPDS data suggests that 0.5% decrement of HbA1c might
translate to an 11.5% reduction in risk of diabetes-related complications.8 Diabetic
subjects already have an atherogenic pattern of risk factors which may be present
for many years before onset and may contribute to the risk of macrovascular
disease as much as the duration of disease itself.4, 30, 31 As shown in the UKPDS 61
and Chapter 2 of this thesis, fasting glucose levels at diagnosis are associated with
improved future perspectives. People presenting with type 2 diabetes with lower
initial glycemia who may be earlier in the course of their disease had fewer adverse
clinical outcomes despite similar glycemic progression.32
By comparing different modalities of glucose lowering treatment in this
observational study, we showed that with intensifying the hypoglycemic treatment,
the number of patients treated with cardiovascular drugs increases and glycemic
control worsens during course of the disease. With respect to adequate treatment
of type 2 diabetes mellitus and its complications this implies that a physician runs
the risk of ‘locking the stable after the horse has bolted’. 
Therefore, it is very important to hold on to the idea of type 2 diabetes as a
progressive and complex syndrome instead of a simple disease characterized by
hyperglycemia, so that early treatment of risk factors can take place and one steps
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in time with the disease. In conclusion, despite deterioration of glycemic control
with intensified glucose lowering treatment, control of other metabolic risk factors
remained stable, probably due to increased prescription of cardiovascular drugs. 
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Abstract
Aim - To investigate the association between antihypertensive medication and
glycemic control in patients with type 2 diabetes, including the potential
modification by glucose lowering therapy. 
Methods - Type 2 diabetes mellitus patients were identified in general practices in a
Dutch middle-sized town from 1994-2000. Comorbidity, laboratory tests, and
blood pressure values and information on drug dispensings were obtained from
general practitioners' files, pharmacy records, and hospital admission data. Glucose
lowering treatment was defined at the moment of the most recent measurement of
the variable of interest. Differences in glycemic control (fasting blood glucose and
HbA1c values) between users and non-users of antihypertensive medication were
compared by analysis of variance. 
Results - More than one third of the patients used any antihypertensive medication.
Users of antihypertensive medication had significantly lower HbA1c values,
increased weight and slightly, non-significant, lower fasting glucose values
compared to non-users. When adjusting for category of diabetes treatment,
duration of diabetes, blood pressure, and body weight, the HbA1c level was even
more lower in patients using antihypertensive drugs (difference 0.5 percent-points,
p< 0.05). The association with glycemic control was present in all categories of
diabetes treatment.
Conclusion - Our study showed that patients with type 2 diabetes mellitus not using
any antihypertensive medication have increased HbA1c levels and lower body
weight. This may indicate a subgroup with predominantly beta-cell failure. 
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Introduction
In patients with type 2 diabetes mellitus antihypertensive drug treatment decreases
both mortality and morbidity.1-3  A special consideration in diabetic patients is the
effect of antihypertensive drugs on glycemic control. For instance, antihypertensive
drugs, such as beta-blockers and diuretics, increase insulin sensitivity.4-6 In
randomized intervention studies with different antihypertensive drugs among
subjects without diabetes both an increased as well as decreased plasma glucose
levels have been reported.7, 8 Because these effects are not limited to one class of
drugs, it may not be a specific drug effect that is independent of blood pressure
lowering. 
It is not well known if the effects of these drugs on glucose metabolism are
also present in patients with type 2 diabetes.9 In the UKPDS hypertension study,
patients treated with atenolol had higher HbA1c levels over the first four years of
follow-up than those randomized to captopril  (7.5% versus 7.0%, p= 0.004),
although during the second four years the levels were the same.10  The FACET
trial compared the effects of fosinopril and amlodipine on serum lipids and
diabetes control in hypertensive type 2 diabetes mellitus patients.11 After 3.5 years,
HbA1c levels in both groups did not differ from the baseline values. The glucose
values showed a small decrease, which was equal in both groups.
The effects probably differ between patients using different glucose
lowering therapy (diet, oral agents, insulin), and may be dependent on the
underlying pathophysiologic mechanism of diabetes. Because type 2 diabetes is a
heterogeneous disease, the effects might vary considerably in daily clinical practice. 
To investigate the associations between antihypertensive medication and
glycemic control in patients with type 2 diabetes mellitus, including the potential
modification by glucose lowering therapy, we performed an observational study in
a population of type 2 diabetes patients treated by general practitioners.
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Patients and Methods
Study setting
This study was performed among patients who received comprehensive primary
care from 17 general practitioners (GPs) in a Dutch middle-sized town (n=50,574).
All GPs used a single electronic medical record system (Medicom®), which was
available for this study, as well as information on drug dispensings from the
pharmacist database (Pharmacom®). Hospital admission and discharge data were
available through the PHARMO Record Linkage System.12, 13  
The following data were available for this study: demographic data, medical
history, comorbidity (including International Classification of  Primary Care (ICPC)
codes), diabetic complications, drug dispensings, prescribing doctor (specialist,
GP), referrals to specialists, and the medical journal (a database-file containing free
text, as recorded by the GP).
To guarantee privacy, all analyses were performed using anonymous records.
Regarding medication prescriptions and dispensings, all drugs were coded
according to the Anatomical Therapeutic Chemical (ATC) Classification. Hospital
diagnoses were coded according to the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM).
Subjects
The study population consists of all cases with type 2 diabetes mellitus as seen by
the network of collaborating GPs (n=17) during 1992-2000 (n=1,144). In the
Netherlands, most patients with diabetes mellitus type 2 visit their GP for regular
check-ups. They were identified from the registries by the use of oral glucose
lowering agents or International Classification of Primary Care (ICPC-2) codes T90 or
T90.2, and/or the description ‘diabetes mellitus type 2’ in their medical records. 
Data from both primary care and the pharmacy based dispensing records
were complete for the period of February 1994 to August 2000 and were available
for the purpose of this study. Subjects in whom the correct diagnosis of type 2
diabetes remained uncertain, due to incomplete and missing data, were excluded
Chapter 4
70
(n=72), as well as patients with no glucose or HbA1c results in their medical files
(n=257). Therefore, the study population consisted of 815 patients with fasting
blood glucose (n=779) and/or HbA1c (n=572) measurements recorded. In patients
with diagnosed type 2 diabetes but unknown date of diagnosis we relied on January
1990 as a reasonable estimate.
Variables of interest
In both cohorts of type 2 diabetic patients, patients with fasting blood glucose or
HbA1c values recorded in their medical file, respectively, we ascertained differences
in metabolic control between users and non-users of antihypertensive medication.
We compared most recent (i.e. last available) measurements of blood glucose and
HbA1c in both groups. Antihypertensive drug use was classified into the major
antihypertensive classes: beta-blockers (C07), angiotensin converting enzyme
(ACE) inhibitors (C09), thiazide diuretics (ATC codes C03A, C03B, C03EA),
calcium channel blockers (C08), and a remaining category of miscellaneous blood
pressure lowering drugs (C02, mainly alpha-blockers). 
We defined users of antihypertensives as patients using any blood pressure
lowering drugs in the half year preceding the last measurement of the glycemic
parameter of interest. Blood pressure was defined at the date of measurement
closest to the date of the most recent glycemic variable, but at least within the
period from 3 months before until 3 months after this recording, otherwise blood
pressure was coded as ‘missing’. We also compared glycemic control in users of
lipid lowering drugs, defined as patients using any serum lipid lowering drug (ATC
group C10) in the half year preceding the last measurement, with glycemic control
in non-users. The diabetic treatment was defined at moment of the last available
measurement of the variable of interest.
Data analysis
For categorical variables, numbers and percentages and for continuous data means
and standard deviations were calculated. For comparison of the continuous
variables between patients who did and did not use antihypertensive medication,
we used the Students’ t-test. Analysis of covariance was used to adjust for potential
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confounding factors, notably age, gender, duration of diabetes, body weight, and
blood pressure. All analyses were performed by SPSS version 10 for Windows.
Results
The clinical characteristics of the study population are given in Table 4.1. Blood
pressure and weight were recorded in a small proportion of the patient files, mainly
in those patients using blood pressure lowering medication. More than one third of
the patients used antihypertensive medication, half of them (52.1%) only one class
of drugs (beta-blocker, ACE-inhibitor, Ca-antagonist, or thiazide diuretic). This did
not result in optimal controlled blood pressure: the average blood pressure in
antihypertensive drug users was 155/87 mmHg, compared to 148/83 mmHg in
non-users (p< 0.01). Use of antihypertensive medication was not associated with
diabetes treatment or recordings of glycemic control (data not shown).
Systolic blood pressure was not associated with glycemic control (p> 0.2). A
higher diastolic blood pressure was associated with a slightly increased fasting
glucose values (regression coefficient 0.035 mmHg/mmolL, CI95%: 0.008-0.061, p<
0.05). There was no association between diastolic blood pressure and HbA1c.
Patients using antihypertensive medication had significant lower HbA1c values,
increased weight and slightly, non-significant, lower fasting glucose values (Table
4.2). When adjusting for category of diabetes treatment (diet, sulfonylureas,
metformin, insulin), duration of diabetes, blood pressure, and body weight, the
HbA1c level was even more lower in patients using antihypertensive drugs
(difference 0.5 percent-points, p< 0.05). 
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Table 4.1 Clinical characteristics at time of glycemic assessment
n=779* n=572†
Age (years) 65.9 (13.1) 65.3 (12.2)
Male 44.3 45.8
Weight (kg) 81.2 (17.6) (n=195) 83.4 (18.6) (n=127)
Diabetes duration (years) 5.0 (5.0) 5.2 (4.8)
Fasting blood glucose (mmol/l) 8.5 (3.1)
HbA1c (%) 7.8 (1.6)
Glucose lowering treatment
- Diet
- Sulphonylureas
- Metformin
- Insulin
18.0
43.8
20.8
17.5
15.4
49.8
19.2
15.6
Switchers to insulin therapy 20.3 20.6
Lipid lowering medication 14.6 14.3
Systolic blood pressure (mmHg) 152.0 (23.0) (n=343) 152.1 (23.2) (n=224)
Diastolic blood pressure (mmHg) 85.1 (11.1) (n=343) 85.5 (11.4) (n=224)
Antihypertensive medications 39.7 34.8
- Beta-blockers
- ACE-inhibitors
- Thiazide diuretics
- Ca-blockers
- Miscellaneous drugs
18.5
23.5
10.9
10.0
0.9
15.4
20.5
9.1
9.4
1.4
* Patients with fasting blood glucose values recorded
† Patients with HbA1c values recorded
Values are means with standard deviation between parentheses, or percentages
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If the analyses were restricted to patients with hypertension based on blood
pressure values (>= 160/95 mmHg), the same associations were found. This was
also when the analyses were performed for each general practice separately. The
association with glycemic control was present in all categories of diabetes
treatment (Figure 4.1). The use of lipid lowering medication (93.9% statins) was not
associated with glycemic control (Table 4.2).
Figure 4.1 HbA1c by antihypertensive medication use
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Table 4.2 Glycemic control by current medication use
HbA1c (%) Fasting glucose
(mmol/l)
Weight (kg)
Currently using antihypertensive medication
- no 8.0 (1.7) 8.6 (3.2) 78.7 (17.0)
- yes 7.6 (1.4)** 8.5 (3.0) 85.0 (18.0)*
Currently using lipid lowering medication
- no 7.8 (1.6) 8.5 (3.2) 80.8 (17.4)
- yes 7.9 (1.6) 8.4 (2.6) 83.2 (18.9)
Values are means with standard deviation between parentheses.
* p< 0.05, ** p< 0.01
Table 4.3 HbA1c and blood pressure by class of antihypertensive medication
HbA1c%) Glucose (mmol/l) Blood pressure (mmHg)
No antihypertensive 8.0 (0.1) 8.6 (0.1) 148/83 (2/1)
Beta-blockers 7.5 (0.3) 8.0 (0.4) 150/86 (4/2)
ACE-inhibitors 7.7 (0.2) 8.5 (0.3) 155/88 (3/2)*
Calcium-antagonists 8.4 (0.5) 9.3 (0.9) 142/80 (7/3)
Thiazide diuretics 7.8 (0.4) 7.4 (0.5) 156/85 (8/2)
Miscellaneous 6.9 (0.5) - † - †
Combinations 7.5 (0.1)* 8.5 (0.3) 158/87 (2/1)**
† No observations
Values are means with standard error between parentheses
* p< 0.05, ** p< 0.01, compared to no antihypertensive use
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The difference in HbA1c was present for all classes, except for calcium-antagonists,
of antihypertensive medication, but only reached statistical significance in the
largest subgroup of patients using drugs from more than one class (Table 4.3). The
same associations were found in the four categories of diabetes treatment, but due
to small numbers these associations were not statistically significant (data not
shown). The fasting glucose levels were slightly lower for all classes of blood
pressure lowering drugs, again as well in each stratum of glucose lowering
treatment. 
Patients using antihypertensive medication started more often with insulin
treatment during the follow-up period (23.9% versus 17.9%, p< 0.05). However,
when adjusting for duration of diabetes the association was no longer present.  
Discussion
In this study we showed that patients using antihypertensive medication had better
glycemic control, notably lower HbA1c levels, and increased body weight. This was
not explained by differences in diabetes treatment, duration of diabetes, or
achieved blood pressure level.
In this observational study, a potential explanation for our findings is that
antihypertensive treatment is driven by glycemic control and vice versa
(confounding by indication). However, if anything, patients with worse glycemic
control are likely to receive more antihypertensive medication, because they are at
an increased risk for vascular complications, and are likely to visit the GP more
often. 
 We found an opposite association, so confounding by indication can not
explain our results. A more probable explanation might be that both use of
antihypertensive medication and better glycemic control are the result of
appropriate treatment of patients with diabetes.14, 15  
However, the absence of an association between lipid lowering medication and
HbA1c level does not support this explanation. 
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Beta-blockers and diuretics increase insulin sensitivity4, 6,  whereas ACE-
inhibitors have a potential protective effect on diabetic nephropathy.16 As a
consequence, patients with type 2 diabetes are more likely to switch to ACE-
inhibitors, and start more frequently with ACE-inhibitors.17  In the hypertension
sub-study of the UKPDS patients were randomized to captopril or atenolol.
Patients given atenolol gained more weight and had higher HbA1c levels in the first
half of the study. However, both treatments reduced blood pressure to the same
extent and were similarly effective in reducing the risk of macrovascular and
microvascular complications of diabetes.10 
Several studies have shown a positive association between blood pressure
and insulin sensitivity.18, 19 Indeed, the 'metabolic syndrome' includes both insulin
resistance and hypertension.20 A few studies have reported lower glucose or HbA1c
levels in type 2 diabetes patients with hypertension (or antihypertensive
medication) compared to normotensive diabetes patients, as found in the present
study.21, 22  In the ABCD trial the HbA1c values continuously decreased in all
treated diabetes patients during the study.23 These results are compatible with the
hypothesis that type 2 diabetes patients without hypertension are a subgroup of
patients with predominant beta-cell failure. Indeed, we found an increased weight
in patients using antihypertensive medication.
The strength of our study is the use of routinely collected primary care data,
which reflect usual clinical practice. General practice networks provide databases
that may fruitfully be used for research.24 A limitation of this approach is the
incompleteness of the data, notably of body weight, which is consistent with other
studies performed in general practice.25 
In conclusion, this study shows that patients with type 2 diabetes mellitus
who do not use any antihypertensive medication have increased HbA1c levels. This
may indicate that this subgroup has predominantly beta-cell failure.
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Abstract
Aim  - Purpose of our study was to determine factors that are associated with
switching from oral hypoglycemic agents to insulin therapy in patients with
diabetes mellitus type 2 in general practice.
Methods – We performed a longitudinal, observational study in a Dutch general
healthcare center. All pharmacologically treated patients with diabetes mellitus type
2 were included (n = 152).  Comorbidity, laboratory results and medication use
were obtained from the general practitioners’ files.
Results - A total of 31 (20.4%) patients switched from oral hypoglycemic agents to
insulin therapy; they were significantly younger at the onset of diabetes, 50.5 versus
57.7 years.  Fasting blood glucose levels and HbA1c values were significantly higher
after the switch compared to patients on oral treatment, 10.0 mmol/l versus 8.4
mmol/l and 8.8% versus 7.9%, respectively. Concerning comorbidity, they
suffered more frequently from acute myocardial infarction, lipid disorders,
depression, retinopathy, and atrial fibrillation. Cardiovascular disease in general was
present more often in patients who switched over to insulin, 77.4% versus 52.9%
(OR 3.1, CI95%: 1.2-7.6).
Conclusions - Patients who switch over to insulin therapy are younger at diagnosis,
suffer from more health problems besides diabetes, especially cardiovascular
disease, and have worse metabolic control, compared with users of oral
hypoglycemic agents.
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Introduction
As type 2 diabetes mellitus (DM) advances, secondary failure of oral hypoglycemic
therapy develops as a consequence of progressive loss of beta-cell function and
worsening of insulin resistance caused by persistent hyperglycemia and possible
development of drug resistance.1 The yearly failure rate of this therapy following an
optimal initial response is approximately 5% tot 10% and increases with duration
of diabetes.2  If oral treatment initially works but later fails (secondary failure),
patients are switched over to insulin therapy.3-6 The increasing number of patients
with type 2 DM and recent insights regarding the importance of strict glycemic
control are expected to result in a larger number of  type 2 diabetic patients
receiving insulin treatment.3
Although the results of the United Kingdom Prospective Diabetes Study
(UKPDS) underline the importance of good glycemic control7, many general
practitioners (GPs) appear hesitant to switch patients over to insulin therapy.8 The
recently updated diabetes mellitus guidelines of the Dutch College of General
Practitioners (‘NHG standaard’) provide no clear indication when insulin should
be given or when the patient should be referred to a specialist.9, 10 
Only a limited number of studies have investigated which factors are
associated with the decision whether or not to convert type 2 DM patients to
insulin therapy and none of these were performed in general practice.11-14
Nevertheless, GPs possess a wealth of information on the health of their patients,
and on many aspects of their medical treatment. 
Therefore, we compared ‘switchers’ and ‘non-switchers’ with respect to patient
characteristics, course of the disease, metabolic control and comorbidity, using a
GP database.
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Materials and methods
Population
This study was carried out among people who were registered in one general
healthcare center in Almere, the Netherlands (n=6800). This healthcare center
offers all aspects of primary care and is staffed by six GPs. Their practices were of
similar size, between 1010 and 1145 patients, and similar in age and sex
distribution. All patient information is stored in one database (Medicom). To
guarantee privacy, all analyses were performed using anonymous records.
 
Study design
The study population consisted of all prevalent cases of type 2 DM and all those
diagnosed during the study period, from January 1995 until June 1999. So, GPs in
our study were still using the first edition of the GPs’ guidelines.9 In the
Netherlands, most patients with type 2 DM visit their GP for regular check-ups.
They were identified from the register by the use of oral hypoglycemic agents or
International Classification of Primary Care (ICPC) codes T90 or T90.2, and/or the
description ‘diabetes mellitus type 2’ in their medical record. Subsequently diet-
treated patients were excluded (n=46).
Medical treatment starts with a first-generation sulfonylurea (tolbutamide),
followed by second-generation sulfonylureas and/or addition of a biguanide or α-
glucosidase inhibitors (in obese patients).9 Diabetes patients are treated according
to a locally developed treatment protocol (‘Diabetes Care Almere’). Patients should
be switched over to insulin therapy if they are on maximized oral medication and
still have HbA1c values greater than 8%.
Following the diabetes care protocol, maximum dosages of oral agents are:
glibenclamide 15 mg per day, gliclazide 240 mg per day, glipizide 20 mg per day,
glimepiride 6 mg per day, and metformin 3000 mg per day.
The protocol included three steps of insulin treatment: 
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1. a single dose of bedtime (long-acting) insulin plus daytime sulfonylurea therapy;
2. two injections of intermediate-acting insulin; 
3. multiple daily injections, combination of short-acting and intermediate-acting
insulin.
The following data were obtained from the anonymous patient records: all
medication prescriptions, demographic data, comorbidity (defined according to
ICPC classification), diabetic complications, doctor in attendance (specialist, GP),
referrals to specialists, and the medical journal (a database file containing free text,
as written down by the GP).
Regarding medication prescriptions, all drugs were coded according to the
Anatomical Therapeutic Chemical (ATC) Classification.15
We defined ‘switchers’ as subjects who switched to insulin therapy (ATC code
A10A) with or without continuation of oral hypoglycemic medication. Some of the
initial patients were already being treated with insulin. 
Microalbuminuria was defined as having at least one measurement of urinary
albumin concentration higher than 20 mg/l. For other continuous variables
(glycosylated hemoglobin (HbA1c), fasting plasma glucose, total serum cholesterol,
body mass index, et cetera) we calculated a mean yearly value per patient and
subsequently a mean value per patient over the whole study period. As we expect
poor controlled patients to have more measurements, this approach gives equal
weight to each subject.
Data analysis 
For the comparison of continuous variables and categorical variables between
switchers and non-switchers, we used the Student’s t-test and chi-square test,
respectively. Odds ratios (ORs) and 95% confidence intervals (CI95%) were
calculated to compare risks of other diseases and disorders, and drug use for those
patients on insulin therapy versus those using oral medication. P-values less than
0.05 were considered statistically significant. We divided the follow-up period of
patients who were switched over to insulin therapy into two phases, before and after
the changeover to insulin therapy.
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The Kaplan-Meier method was used to calculate the cumulative incidence of
switching over to insulin among the cases present in 1995. Survival time was
defined as months on oral hypoglycemic treatment. So, the cumulative incidence of
switching was calculated as: 1 - cumulative survival probability. All analyses were
carried out using the statistical package SPSS, version 9.0 for Windows.
For descriptive variables without further statistical testing, for instance to
determine reasons for not switching despite secondary failure of oral treatment, the
medical journal as registered by the GP was used. 
Results
Figure 5.1 shows the number of type 2 diabetic patients, excluding those on dietary
treatment only, during the study period. Between 1995 and 1999 there was an
increase in the total number of patients diagnosed with type 2 diabetes mellitus; 72
patients in 1995 increasing to 136 patients in 1999. Two of the initial patients
enrolled were already on insulin therapy. The estimated prevalence of diabetes
mellitus type 2 at June 30th 1999 was 2.1% (136/6510; CI95% 1.7% - 2.4%).
Figure 5.1 Insulin treatment over time in a healthcare center in Almere
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In the study, 79 men and 73 women, aged between 32 and 94 years (mean age 62.8
years), with diabetes mellitus type 2 were enrolled. Their clinical and demographic
characteristics are given in Table 5.1. During the study period 14 patients died,
three in the insulin-requiring group. Two patients moved out of the country in
1997. 
Table 5.1 Characteristics of type 2 diabetic patients
Variable N = 152
Age at onset (yrs) 56.3 ± 1.2
Male (%) 52.0 ± 4.1
Duration of disease (yrs) 5.8 ± 0.5
Fasting blood glucose (mmol/l) 8.7 ± 0.2
HbA1c (%) 8.0 ± 0.2
Systolic blood pressure (mmHg) 149.3 ± 1.9
Diastolic blood pressure (mmHg) 85.2 ± 0.8
Total serum cholesterol (mmol/l) 5.8 ± 0.1
HDL cholesterol (mmol/l) 0.7 ± 0.1
Triglycerides (mmol/l) 1.2 ± 0.1
Body mass index (kg/m2) 31.6 ± 0.7
Weight (kg) 85.4 ± 1.5
values are proportions or means ± standard error of the mean (SEM)
HDL = high-density lipoprotein; HbA1c = glycosylated hemoglobin
Conversion to insulin therapy
Of 152 patients, 31 (20.4%) switched from oral hypoglycemic agents to insulin
therapy. The cumulative incidence of switching to insulin treatment among
prevalent cases in 1995, with a mean diabetes duration of 5.9 years, was 36% (CI95%
23%-48%) in June 1999. Before switching, 16 patients (62%) were on the
maximum dosage of a sulfonylurea derivative (SU), while 12 (46%) patients used a
SU in combination with metformin. Four patients (15%) had an obvious or
plausible reason for switching over to insulin without maximizing oral medication
in accordance with the guidelines; two had a myocardial infarction, one wished to
become pregnant and another patient had no adequate response to oral
hypoglycemic agents within 6 weeks. In total 22 patients (75%) were referred to
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diabetiologist or were hospitalized at the moment they switched to insulin therapy.
After stabilization of their metabolic state, in 18 patients (85%) diabetes care was
continued by their GP. 
Reasons for not switching
Within the study population ten patients did not switch to insulin therapy despite
secondary failure of oral hypoglycemic agents, defined by latest HbA1c  equal to or
greater than 8.0 %, and maximal treatment with oral hypoglycemic agents.
Subsequently, we identified reasons for not switching, according to the GP, by
examining the medical journal.  The main reasons for not switching were:
resistance (n=6), hesitation or unwillingness to undergo insulin therapy (n=1), and
non-compliance with appointments (n=2) and medication regimen (n=5). Two of
these patients were already self-monitoring their blood glucose levels. The reasons
for not switching remained unclear in two patients.
Switchers in comparison to non-switchers 
The differences between type 2 diabetic patients treated with insulin and patients
on oral hypoglycemic agents are listed in Table 5.2. Patients switching over to
insulin therapy, were significant younger at the onset of the disease, and had a
shorter duration of diabetes (4.0 versus 4.8 years). At the end of the study period,
there was no significant difference in age between the two groups; the mean age
for switchers was 60.7 (± 13.1) years, compared to 63.4 (± 14.3) years in the
patients who did not switch over to insulin. The fasting blood glucose and HbA1c
values of insulin users compared to users of oral hypoglycemic agents were
significantly higher after the switch (p= 0.01 and p= 0.02, respectively). 
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Table 5.2 Insulin users compared to users of oral hypoglycemic agents
Measure Insulin therapy
Before switch
(N=31)
After switch
No insulin therapy (N=121)
Age at onset (yrs)* 50.5 ± 2.2 57.7 ± 1.3
Duration of disease (yrs)* 4.0 ± 1.3 2.6 ± 0.2 4.8 ± 0.5
Cigarette smokers (%) 50.0 64.0
Fasting blood glucose (mmol/l)† 8.8 ± 0.6 10.0 ± 0.6 8.4 ± 0.2
HbA1c (%)† 8.5 ± 0.3 8.8 ± 0.4 7.9 ± 0.2
Total serum cholesterol (mmol/l)‡ 6.4 ± 0.2 5.8 ± 0.2 5.7 ± 0.1
Systolic blood pressure (mmHg) 156.3 ± 6.1 155.8 ± 4.9 148.1 ± 2.0
Diastolic blood pressure (mmHg) 86.0 ± 3.1 85.5 ± 2.3 85.0 ± 0.9
Body mass index (kg/m2)§ 32.8 ± 2.5 31.3 ± 1.6 31.8 ± 0.9
Weight (male)§ 82.3 ± 6.2 91.3 ± 3.9 88.3 ± 2.3
Weight (female)§ 95.0 ± 6.3 84.1 ± 6.3 80.8 ± 2.4
Diabetic complications
Microalbuminuria|| 53.8 37.8
Retinopathy* 19.4 6.6
Neuropathy 16.1 5.8
Other medical disorders (number)* 7.0 ± 0.9 4.5 ± 0.3
values are proportions or means ± SEM
* p-value < 0.05, insulin users compared to users of oral hypoglycemic agents
† p-value < 0.05, insulin users, after switch, compared to users of oral hypoglycemic agents 
‡ p-value < 0.05, insulin users, before switch, compared to users of oral hypoglycemic agents
§ sparse data about BMI and weight before switch (2 and 11 respectively) 
|| urinary albumin concentration ≥ 20 mg/l
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Before these patients were converted to insulin therapy they had significantly
higher total serum cholesterol levels, 6.4 mmol/l versus 5.7 mmol/l (p= 0.04). 
Microalbuminuria was present in patients on oral hypoglycemic agents (OHA)
about as frequently as in those treated with insulin. But we also found that the
urinary albumin concentration was less tested in insulin-treated patient than in
those on OHA, 41.9% versus 61.2% (OR 0.5, CI95%: 0.2-1.0). Retinopathy and
neuropathy were more frequent in insulin-treated patients, although the difference
in prevalence of neuropathy was borderline significant; odds ratios were 3.4 (CI95%:
1.1-10.6) and 3.1 (CI95%: 0.9-10.7) respectively. 
Comorbidity
Comorbidity, defined as a health problem besides diabetes in the GP list, was
present in 31 (100%) of the switchers and 106 (87.6%) of the subjects that were
not converted to insulin therapy (p= 0.04).
Patients who were converted to insulin therapy had more comorbidity, notably
acute myocardial infarction (OR versus non-switchers 3.5, CI95%: 1.3-9.6),
depression (OR 14.3, CI95%: 2.7-74.9), disorders in lipid metabolism (OR 2.9, CI95%:
1.1-7.8), and atrial fibrillation (OR 8.8, CI95%: 1.5-50.6). Of borderline significance
were the higher frequencies of benign prostate hypertrophy (OR 6.4, CI95%: 1.0-
40.0) and chronic obstructive pulmonary disease (OR 4.3, CI95%: 1.0-18.4) in
patients on insulin. Cardiovascular disease in general was present more often in the
patients that were switched over to insulin therapy, the prevalence was 77.4%
versus 52.9% (OR 3.1, CI95%: 1.2-7.6). 
All diseases mentioned usually occurred before patients converted to insulin
therapy; these percentages varied between 63.6% (acute myocardial infarction) and
100% (benign prostate hypertrophy).
 
Co-medication
Drugs most frequently prescribed besides the hypoglycemic medications were
analgesics, non-steroid anti-inflammatory drugs, psycholeptics, antibiotics, and
antimycotic drugs. Of the patients on insulin treatment, 83.9% used one or more
cardiovascular drug(s), identified as groups B01, C01-C03 and C07-C10 following
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the ATC classification, versus 62.8% in subjects on oral treatment only (OR 3.1,
CI95%: 1.1-8.6). When we inspected the cardiovascular medication further, patients
on insulin used about twice more frequently cardiacs, angiotensin converting
enzyme inhibitors, lipid lowering medication and antithrombotic agents, ORs were
2.9, 3.0, 3.2 and 2.5 respectively (Table 5.3).
Table 5.3 Medication use in insulin using versus non-insulin using patients
Generic name ATC* % use Odds Ratio [95% CI]
Cardiacs C01 45.2 v 22.3 2.87 [1.25 – 6.55]
Diuretics C03 41.9 v 28.9 1.78 [0.79 – 4.01]
Beta blocking agents C07 35.5 v 28.1 1.41 [0.61 – 3.25]
Calcium channel blockers C08 29.0 v 20.7 1.57 [0.64 – 3.83]
ACE inhibitors† C09 58.1 v 31.4 3.02 [1.35 – 6.80]
Other antihypertensive drugs‡ C02 12.9 v 1.7 8.82 [1.53 – 50.63]
Lipid lowering medication C10 38.7 v 16.5 3.19 [1.34 – 7.59]
Antithrombotic agents B01 54.8 v 33.1 2.46 [1.10 – 5.49]
Antidepressants N06A 12.9 v 7.4 1.84 [0.53 – 6.44]
Anti-asthmatics R03 35.5 v 25.6 1.60 [0.69 – 3.70]
* ATC = Anatomical Therapeutic Chemical classification
† ACE = Angiotensin converting enzyme
‡ including for instance antiadrenergic agents (doxazosin), agents acting on arteriolar smooth
muscle (hydralazine),  serotonin antagonists (ketanserin)
Switching to insulin in general practice
91
Discussion
This study describes patients with diabetes mellitus type 2 who switched from oral
hypoglycemic agents to insulin therapy in a primary care setting. Several factors
potentially associated with the decision to convert to insulin therapy were found,
notably: younger age at diagnosis, more comorbidity, worse metabolic control, and
use of more cardiovascular medication.  
The study population consisted of all prevalent cases of type 2 DM and all
those diagnosed during the study period, from January 1995 until June 1999. So,
the updated GPs’ guidelines on type 2 diabetes mellitus, introduced in 1999, were
not implemented in primary care yet.10 Important changes compared with the
earlier edition of the guidelines9 - used by the GPs in our study - are the shortening
of the dietary period from six to three months and the introduction of metformin
as first-choice medical therapy in obese patients (body mass index > 27 kg/m2).10
However, both aspects are not likely to influence the associations we found
between some patient characteristics and switching to insulin therapy in type 2
diabetes.
General practice networks provide databases that may fruitfully be used for
research. The use of computerized databases permits analysis of diagnostic,
treatment and prescribing patterns in different patient groups within the general
population. These databases enhance access to health related information of large
groups of patients over a long period of time.16, 17 The sensitivity of general
practice registers in identifying patients with diagnosed diabetes exceeds 90%.18
The prevalence of 2% which we found in this GP population closely approximates
the estimated prevalence in the Netherlands.19, 20 Also, the increase in diabetes is in
agreement with the trend reported for the Netherlands. The increase is based on
both the ageing of the population and increased awareness of diabetes among
GPs.21  One advantage of using data derived from a healthcare center is the
uniform approach to the treatment. GPs and district nurses cooperate closely,
following to a local developed treatment protocol. However, the individual
physicians all make their own decisions. Because of the strict protocol, the effect of
variability will be limited.  
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Data on body mass index and smoking were very incomplete (available in
27.6% and 43.4% of the patients, respectively). Given the high mean values (Tables
5.1 and 5.2) it seems that GPs only record these characteristics in obese and
smoking patients. Although most patients are weighed regularly, body height was
seldom measured. Our main results did not derive from these variables, so there
was no influence on the associations we found. 
Secondary failure to treatment with oral hypoglycemic agents is defined as
an inadequate glucose-lowering effect of oral drugs after an initial good response.11-
13 Failure implies that the whole treatment strategy failed, not simply the drug
treatment.12  The causes of failure include non-compliance, weight gain, declining
beta-cell function, infection, and the use of diabetogenic drugs, such as
glucocorticoids, thiazides, and beta-blockers.11  In our study, the cumulative
incidence of switching to insulin therapy was 36% over a 4.5 year period, which is
comparable to other studies.22-24 After nine years of follow-up in the U.K.
Prospective Diabetes Study (UKPDS), 30% of the patients had switched over to
insulin treatment.23
Groop and colleagues concluded that secondary failure to treatment with
oral hypoglycemic agents is determined by the disease itself rather than by patient-
related factors.11  The presence of islet cell and thyrogastric antibodies can unmask
a distinct group of type 2 diabetic patients with a high risk of secondary drug
failure and subsequent insulin dependency.12  However, this is probably only a small
proportion of the patients who become insulin users.
Although experimental studies show that insulin therapy can be save and
efficacious in improving glycemic control in type 2 diabetes.7, 25, 26 little is known
about factors determining the decision to use insulin in type 2 DM. In a
randomized controlled trial (UKPDS 26), higher failure rates were found in those
with higher glucose concentrations, those who were younger, those with lower
beta-cell reserve and those randomized to glibenclamide compared with
chlorpropamide.27 In the literature we found no studies that described
determinants in type 2 diabetic patients associated with switching over from oral
hypoglycemic agents to insulin therapy in primary care. Goddijn studied
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prospectively a cohort of type 2 diabetic patients referred by general practitioners
to an outpatient department for consideration of insulin therapy. As in our study,
she found that switchers had a higher HbA1c. However, in contrast to our findings,
her patients had a lower body mass index and had been taking oral hypoglycemic
agents longer.13 These differences might indicate that GPs wait longer to refer
patients for insulin than switching the patients themselves. In addition, the study of
Goddijn was performed a few years ago. Since then GPs seem more likely to
switch to insulin therapy, probably because of the increased awareness of strict
glycemic control.
It is well known that diabetic patients suffer from more (cardiovascular)
morbidity than subjects without diabetes.28, 29 In addition, we found that insulin
users suffered more frequently from other diseases besides diabetes. Also the
higher frequency of depressive disorders has been described elsewhere. Among
other things, depression is associated with poorer medication regimen adherence.30
Furthermore, 64% to 100% of these disorders developed or occurred in the period
before patients converted to insulin, suggesting that the course of the disease in
diabetic patients who eventually switch over to insulin therapy is more severe. The
younger age of onset and shorter duration of diabetes in these patients further
support their increased severity.
The UKPDS has shown that more intensive management aiming for near-
normal glucose levels reduces the risk of diabetes-related complications,
particularly microvascular disease.7 This suggests that physicians should be on the
alert for patients with secondary failure who should be converted to insulin therapy
in time. 
Our results suggest that insulin therapy is started after the development of
diabetic complications and other comorbidity; in other words, ‘one locks the stable
after the horse has bolted’.
In conclusion, we found that patients who switch over to insulin therapy due to
secondary failure are younger at diagnosis, more frequently suffer from depression,
acute myocardial infarction, lipid disorder, atrial fibrillation, and retinopathy and
have higher HbA1c and total serum cholesterol values. 
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CHAPTER 6
Refill Compliance in Type 2 Diabetes
Mellitus: a Predictor of Switching to
Insulin Therapy?
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Abstract
Aim - To assess whether switching to insulin therapy in patients with type 2
diabetes mellitus is associated with medication refill compliance of oral
hypoglycemic agents.
Methods - The PHARMO Record Linkage System was used as data source for this
study. Patients with newly treated type 2 diabetes mellitus were defined as subjects
in whom oral hypoglycemic therapy was initiated between 1991 and 1998. We
performed a matched case-control study in this cohort. Cases were patients who
switched to insulin therapy. Date of switching in the case was defined as the index
date. Controls were subjects still on oral therapy on the index date, matched on
duration of diabetes and calendar time. We measured the medication refill
compliance in the year starting 18 months before the index date and calculated
various compliance indices.
Results - In total, 411 cases and 411 matched controls were identified. Cases
suffered more often from more severe comorbidity and used a higher number of
oral hypoglycemic agents and concomitant non-diabetic drugs. The overall
compliance rate did not differ significantly between cases and controls, the
adjusted OR was 1.3 (CI95%: 0.6-2.8).
After performing multivariate logistic regression modeling, age at onset of diabetes,
gender, comedication, combination therapy, and daily dosage frequency, were
independently related to switching.
Conclusion - We were unable to confirm the hypothesis that noncompliance with
treatment is more prevalent in patients with secondary failure. Other variables, like
comorbidity and disease-related factors seem to play a more important role in
switching to insulin therapy.
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Introduction
Oral hypoglycemic agents are the major treatment for people with type 2 diabetes
mellitus. As type 2 diabetes mellitus advances, secondary failure of oral
hypoglycemic therapy develops as a consequence of progressive loss of beta-cell
function and worsening of insulin resistance caused by persistent hyperglycemia
and possible development of drug resistance.1, 2 Each of the available oral
hypoglycemic agents has limited glucose-lowering efficacy and many patients
eventually require insulin to avoid marked hyperglycemia.3 
Furthermore, other factors, such as severity of the disease itself and younger age at
diagnosis, may contribute to disease exacerbations leading to a switch to insulin
therapy due to secondary failure.4, 5
Noncompliance with prescribed regimens is one of the main causes of poor
metabolic control in patients with diabetes.6 An estimated 10-30% of patients with
type 2 diabetes withdraw from their prescribed regimen within 1 year of diagnosis
and, of the remainder, nearly 20% administer insufficient medication to facilitate
an adequate reduction in blood glucose.7
‘Compliance’ has been defined as an attempt by patients to take their medication
each day as prescribed, or the extent to which the patient’s actual history of drug
administration corresponds to the prescribed regimen.8 Patients typically take less
medication than they have been prescribed. In several studies assessing adherence
to glucose lowering regimens, overall compliance rates between 64 and 83% were
found for oral hypoglycemic agents.9-12 
The prescription refill records of centralized pharmacies are a potential
source of information about patient compliance. Based on the assumption that a
patient cannot be compliant when he has not obtained sufficient medications, refill
compliance can be measured.13
Population-based studies of refill compliance showed that many, if not most,
patients fail to continue medication intended for long-term use14; therapy
discontinuation rates for oral hypoglycemic agents varied between 8 and 16% per
year.10, 15 Noncompliance of oral hypoglycemic agents results in decreased glycemic
control, which falsely indicates secondary failure and unjustified initiation of insulin
therapy. 
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The purpose of the present study was to assess whether switching to insulin
therapy in patients with type 2 diabetes is associated with medication refill
compliance of oral hypoglycemic agents. 
Patients and methods
Data source
The PHARMO Record Linkage System (PHARMO RLS) was used as data source
for this study. The PHARMO RLS comprises pharmacy dispensing records linked
to hospital discharge data of all community-dwelling residents of eight Dutch
cities, counting for more than 450,000 patients histories, from 1985 onwards.16, 17
Drugs are coded according to the Anatomical Therapeutic Chemical (ATC)
Classification.18 Because in the Dutch health care system patients are usually
designated a single pharmacy to fill their prescriptions independent of prescriber,
virtual complete data are available for each subject. These data include sex, date of
birth, drug names with ATC codes, dispensing date, total supply, prescribed dosage
regimen, prescriber, dates on admission and discharge from hospital, and discharge
diagnoses. 
Study subjects
Patients with newly treated type 2 diabetes mellitus were defined as subjects in
whom oral hypoglycemic therapy was initiated between 1991 and 1998. The date
of starting oral hypoglycemic treatment was presumed to approximate their date of
clinical diagnosis. Patients were eligible for inclusion in the cohort if they received
no hypoglycemic medication during 180 days (half a year) preceding the date of
starting oral hypoglycemic agent use. Furthermore, patients were only included if
they were dispensed at least two consecutive prescriptions of oral hypoglycemic
agents. 
We performed a matched case-control study, nested in this cohort of
patients with type 2 diabetes. Cases were patients initially treated with oral
hypoglycemic agents who added or switched to insulin therapy. Date of switching
Chapter 6
102
in the case was defined as the index date for each matched pair. Their medication
history of oral hypoglycemic therapy before the switch was at least 18 months.
Controls were subjects still on oral therapy on the index date. We matched cases
and a similar number of controls on calendar time (quarter of the year) of first
prescription of an oral hypoglycemic agent. From the 430 cases who met the
inclusion criteria, 16 were excluded because they discontinued their oral therapy in
the 18 month-period before the index date. Discontinuation of pharmacotherapy
was defined as a gap of at least 365 days (a year) during which the patient used no
hypoglycemic agents at all. For three cases, the matching procedure was not
successful. Eventually, these additional exclusions left 411 cases and 411 controls
for study. 
Medication use
In general, Dutch pharmacy policy limits the quantity of medications dispensed at
one time to a 3-month supply and requires physicians to write new prescriptions at
six-month intervals. All prescriptions for oral hypoglycemic agents (sulfonylureas,
biguanides, or alpha-glucosidase inhibitors) were retrieved. Both for the cases and
controls, we measured the medication refill compliance in the year starting 18
months (a year and a half) before the index date (called ‘risk window’), excluding
the half-year period before the index date. 
Visualized:
Risk Window (1 year) Black Period (½ year) After Indexdate
                        ↑ = indexdate
The reason we disregarded this ‘black period’ is because we knew from clinical
practice and research experience that this episode just before a switch to insulin is
frequently featured by cluttered and erratic drug use patterns, with several oral
hypoglycemic agents prescribed at the same time and often an unclear dosage
regimen, due to the lack of adequate glycemic control in this period.
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With regard to drug regimen characteristics and complexity, three variables
were created from the prescription profile of each patient: the average number of
doses per day of oral hypoglycemic agents, presence of combination therapy
(concomitant use of more than one hypoglycemic agent), and the number of
concurrent medications other than hypoglycemic drugs. 
Ascertainment of refill compliance
The pharmacy data were used to calculate the compliance measure on the basis of
an index previously developed and validated by Steiner et al.13 The intended
duration of every oral hypoglycemic agent prescription was calculated from details
on the dispensing (total amount dispensed and drug regimen). Firstly, we calculated
MED_INT (Medication-Interval) for all successive prescriptions during the
exposure window.  MED_INT is the ratio of days’ supply obtained at the
beginning of a specific time interval to the days elapsed before the subsequent
refill. For a series of refill intervals, an overall measure of compliance, MED_TOT
(Medication-Total), was calculated as the total supply of pills dispensed divided by
the total number of days elapsed. 
Because measures of medication availability may fail to identify clinically
meaningful treatment gaps, we also calculated a third compliance index,
MED_OUT (Medication-Out). MED_OUT was defined as the total number of
days without medications divided by the total days of observation. So, if it comes
to perfect compliance, i.e. continuous drug availability, MED_TOT = 1 and
MED_OUT = 0. Subsequently, different categories of compliance were created
from these continuous indices. A classification of undercompliance (‘gap’) was
given if the patient refilled the prescription more than 7 days after the expected
date or MED_INT was < 90%. A classification of overcompliance (‘oversupply’)
was given if the patient refilled the prescription more than 7 days before the
expected date or MED_INT was > 110%. Relative over- and undercompliance
was assessed by dividing the total number of oversupplies and gaps, respectively,
by the total number of dispensings. 
Furthermore, we looked at compliance as a dichotomous measure and
considered patients to be sufficiently compliant with their treatment when at least 
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80% of the days in the study period were covered.19, 20 Since the outpatient
pharmacies do not record prescriptions dispensed during an inpatient admission,
the number of days spent in the hospital was included in the model to control for
possible underestimation of compliance due to hospitalizations.
      
Comorbidity
An individual’s morbidity and overall health status was assessed using the chronic
disease score (CDS), a validated measure of chronic medical conditions based on
medications used.21-23 The CDS was calculated by assigning scores (0 – 5) to classes
of drugs according to the severity of the disease for which they were prescribed
during a one-year period, the (hypothetical) maximum total score is 35. Because
the study population comprised patients with type 2 diabetes mellitus, the
minimum score was 2. For example, a CDS of 7 or more is associated with a
fivefold increase in the risk of hospitalization and a tenfold increase in the risk of
death.21
Statistical Analysis
We performed conditional logistic regression analysis to estimate matched odds
ratios (ORs) with respect to the different compliance indices for cases compared to
controls, and 95% confidence intervals (CIs), using EGRET.24
With regard to potential confounding, we controlled for age, sex, drugs regimen
characteristics, days of hospitalizations, and comorbidity as measured by the
chronic disease score. We used chi-square (categorical variables) and Mann-
Whitney (continuous variables) tests to evaluate differences in general
characteristics between cases and controls.
Furthermore, we performed multivariate conditional logistic regression analysis to
define a model including only strong and/or known predictors of switching to
insulin therapy.
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Results
In this nested case-control study, 411 cases (patients who switched to insulin) and
411 matched controls (those who did not switch) were identified in the period
from 1991 to 1998. General characteristics are given in Table 6.1. There was a
borderline significant difference with respect to sex distribution in cases and
controls (50% versus 44% males, respectively, p= 0.06). The mean chronic disease
score, as an indicator of morbidity and overall health status, was not different in
cases and controls (5.7 versus 5.3, p= 0.07). Severe (co)morbidity (CDS> 7) was
more prevalent in cases compared to controls (28% versus 18%, p= 0.001). In
total, 112 (13.6%) patients were hospitalized during the one-year exposure period,
the maximum number of hospitalizations was 6. With respect to concomitant drug
use, cases used on average one (not hypoglycemic) drug more than controls (p=
0.004). Cases were about twice more likely to use more than one hypoglycemic
agent; 239 (58%) cases received combination therapy, compared to 120 (29%) of
the controls (p< 0.001). The most common combination was a second-generation
sulfonylurea derivative with metformin (59%), followed by two different
sulfonylureas (16%) and a second-generation sulfonylurea with acarbose (12%).
Table 6.2 presents various ascertained compliance indices in cases and controls.
The overall compliance rate (MED_TOT) and MED_OUT did not differ
significantly between cases and controls. The crude OR for MED_TOT was 1.5
(CI95%: 0.8-2.8). In addition, after controlling for comorbidity (CDS,
hospitalizations), drug regimen characteristics (dosage frequency, combination of
oral hypoglycemic therapy, concurrent medication), and patient characteristics
(gender, age at onset), the adjusted OR was 1.3 (CI95%: 0.6-2.8). With respect to the
different oral hypoglycemic agents, mean compliance rates varied between 96.2%
(glimepiride) and 99.3% (acarbose). Compliance was related to frequency of dosage
and varied between 98.1% (once or twice daily) and 93.6% (three or more times
daily), p= 0.01. When we considered patients sufficiently compliant with an overall
compliance rate of at least 80%, 86.1% of the cases and 83.5% of the controls were
compliant, this difference was statistically not significant (p= 0.29). Relative
overcompliance was more prevalent in cases (32% versus 28%, resp.) with a
matched OR of 1.9 (CI95%: 1.0-3.7). With respect to relative undercompliance,
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cases and controls were comparable (33% versus 34%, respectively). When
compliance was defined as 1-MED_OUT, mean compliance was 85.3±15%.
As presented in Table 6.3, the following variables were related to switching:
gender, age at onset of diabetes, comedication, combination therapy (simultaneous
use of more than one oral hypoglycemic agent), daily dosage frequency.
Overcompliance , defined as a mean overall compliance rate higher than 110%,
was a borderline significant determinant (p= 0.07).
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Table 6.1 General characteristics of the study population
Variable Cases (N=411) Controls (N=411) P-value
Male sex (%) 207 (50%) 180 (44%) 0.059
Age at onset* (yrs) 59.0 ± 0.6 65.0 ± 0.6 <0.001
Calendar year of onset* 1993.9 ± 0.07 1993.9 ± 0.07 …
Duration of disease† (yrs) 3.5 ± 0.07 3.5 ± 0.07 …
Age at switching (yrs) 62.5 ± 0.6 … …
Chronic Disease Score:
2 95 (23%) 105 (26%) 0.416
3-5  110 (27%)  120 (29%) 0.437
6-7 93 (23%) 113 (27%) 0.107
>7 113 (28%) 73 (18%) 0.001
Comedication (total number of drugs)‡ 8.3 ± 0.3 7.0 ± 0.2 0.004
Number of hospitalizations‡
0 351 (85%) 359 (87%) 0.416
1 40 (10%) 41 (10%) 0.907
>=2 20 (5%) 11 (3%) 0.099
Drug regimen
1. Monotherapy 172 (41.8%) 291 (70.8%) <0.001
    OHA§:         Tolbutamide 34.9 50.9 0.001
Glibenclamide 37.8 22.7 <0.001
Gliclazide 18.0 19.6 0.678
Glimepiride 4.1 0.3 0.003
Metformin 5.2 5.5 0.903
Acarbose 0 1.0 0.182
2. Combination therapy 239 (58.2%) 120 (29.2%) <0.001
Number of OHAs§ 1.8 (1-4) 1.3 (1-3) <0.001
Daily dosage frequency 2.1 (1.0-3.7) 1.9 (1.0-4.0) <0.001
Data are means ± SEM or numbers; variance or percentages between parentheses
* date of first prescription of oral hypoglycemic agent
† at indexdate, i.e. date of switching to insulin therapy of the cases
‡ during the one year period refill compliance was measured
§ OHA: oral hypoglycemic agent, with respect to use of OHAs, percentages are given
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Table 6.2 Compliance indices in cases and controls
Outcome variable Cases (N=411) Controls (N=411)
Compliance rate (MED_TOT) 0.98 (0.17-2.39) 0.96 (0.24-1.55)
 Compliance category*:    <0.70 9.2 10.0
0.70-0.89 16.3 16.5
0.90-1.10 51.6 58.4
1.11-1.30 18.2 10.7
>1.30 4.6 4.4
MED_OUT 0.15 (0-0.86) 0.14 (0-0.76)
variance or percentages between parentheses
* with respect to compliance categories, percentages are given
Table 6.3  Determinants of switching to insulin therapy*
Variable OR CI95%
Gender (1=male) 1.45 1.04-2.03
Age at onset (per year) 0.96 0.94-0.97
Comedication (per extra drug)† 1.08 1.04-1.11
Glucose lowering combination therapy (1=yes) 3.44 2.36-5.03
Daily dosage frequency 1.34 1.03-1.74
Undercompliance‡ 1.07 0.72-1.57
Overcompliance‡ 1.51 0.96-2.36
* multivariate conditional logistic regression modeling
† number of drugs besides hypoglycemic medication
‡ undercompliance: overall compliance rate< 90%; overcompliance: overall compliance rate >
110%; reference category: overall compliance rate 90-110%
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Discussion
We measured refill compliance with oral hypoglycemic therapy among patients
who switched to insulin therapy and those who did not. The finding that
compliance was only borderline associated with switching does not support the
hypothesis that noncompliance with treatment is more prevalent in patients with
secondary failure. 
A recent study by Evans et al  for the DARTS/MEMO collaboration
showed similar results, they found in a comparable diabetic population even
significantly improved compliance in patients who did commence insulin (100.4%
versus 92.9% in non-switchers, p< 0.001).25 Other variables, like patient and drug
regimen characteristics seem to play an important role in explaining switching to
insulin therapy.
Pharmacy records provide a reliable tool to measure drug exposure when
compared with home inventory (e.g., a comparison between the prescribed
medication vs. the medication in the patient’s home) or pill count.9, 26  One
important advantage is avoidance of any Hawthorne effect (i.e., improvement of
performance when the subject is under observation) by assessing compliance
retrospectively by review of prescription-refill records.27 Furthermore, it is known
that observational studies of drug exposure can be more accurately estimated from
dispensing rather than prescribing data, for example, Beardon et al  found an
overall rate of non-redemption of 5.2% with regard to prescriptions.28 Paes and his
colleagues already proposed that the use of refill data might be especially useful in
the community pharmacy setting.9 One advantage of this method is that pharmacy
computers can deliver a signal if the patient is too late for his or her refill.7 It
provides the possibility to monitor a large number of patients without extra
investments.
Compared to similar studies, we found a reasonably high overall compliance
rate of 97%.9, 10, 12, 30 For example, Paes et al  examined the compliance as registered
by MEMS® (Medication Event Monitoring System) devices of a group type 2
diabetes mellitus patients.12 They excluded patients using a weekly dose organizer
(a substantial part in an elderly population). They found an overall compliance of
74.8%, but compliance was strongly related to frequency of dosage and varied
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between 98% (once daily) and 66% (three times daily). We found that higher
complexity of the dosage regimen (more comedication, use of combination therapy
and higher number of dosages per day) was also associated with a higher risk of
switching. 
This finding supports the ‘stepping stone theory’, intrinsic to secondary
failure. Before the ultimate switch to insulin, intermediate steps due to gradually
worsening of metabolic control are taken, like raising the doses and addition of
other oral hypoglycemic agents. When we defined compliance as 1-MED_OUT,
our results were compatible with a study by Venturini11, mean compliance rates
were 85% and 83%, respectively. 
Refill compliance measures, however, have inherent limitations. First, and
most important, refill compliance measures cannot assess the relationship between
the duration of drug action and the timing of doses, which has a critical impact on
the efficacy of treatment in diabetes. Studies with reliable compliance assessment
have shown that the main error patients make is to take the prescribed dose at
longer-than-prescribed intervals – often by hours.29 Other cons of this method are
that nothing can be said about patients getting their refills on time, the cause of
noncompliance is unknown and in general the results will overestimate
compliance.9 For instance, it is quite common for a person to cash a repeat
prescription several days before they need it for reason of convenience. However,
the occurrence of this phenomenon is not expected to be different between cases
and controls. Besides that, measures of treatment gaps make the assumption that
both embedded and terminal gaps are due to noncompliance by the patient rather
than drug discontinuation by the clinician. 
Unfortunately, the computerized pharmacy records only provide
information on the dosage regimen at the time the prescription is filled, interim
changes by the physician remain unobserved. The fact that we did not reveal any
difference in compliance rates between cases and controls could be due to interim
changes to the drug regimen. Cases are more likely to receive increasing doses in
response to their poor glycemic control, resulting in an overestimation of the
compliance rate. It is important to realize that if the daily dose changes, so does the
duration of supply on hand. For example, if a patient were instructed to double his
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daily dose, his residual days’ supply would be halved. Hence, the refill compliance
measurement would be an overestimation of reality. After all, relative
overcompliance was substantially higher in the cases. Nevertheless, the high
specificity of refill compliance allows identification of a subset of individuals who
cannot be taking enough medication to attain a treatment goal, because they have
not obtained enough drugs in the pharmacy.14 
Within the diabetes literature, the tendency has been to treat adherence and
metabolic control as interchangeable constructs.6, 31 Adherence is one factor, but
not the only factor, which may influence a patient’s metabolic status only when an
effective treatment regimen has been prescribed by the physician.6 Although early
addition of other agents may delay the increasing hyperglycemia, each of the
available oral hypoglycemic agents has limited glucose-lowering efficacy and many
patients eventually require insulin to avoid marked hyperglycemia (i.e. secondary
failure). In the UKPDS, the worsening of glycemic control has been attributed to
the natural course of type 2 diabetes and lack of efficacy of current
antihyperglycemic therapy.3 We showed that besides adherence, other, sometimes
unchangeable factors (e.g. age and gender) are strong predictors of switching to
insulin therapy.
In conclusion, we found that noncompliance in general was not associated
with switching to insulin in type 2 diabetic patients. In the near future, it could be
useful to explore the relationship between ‘timing compliance’ (timing of doses)
and metabolic control using the MEMS® method. We suggest that other factors
independent of a patient’s willingness to adhere to a treatment regimen, like
disease-related factors, are more relevant in explaining secondary failure in most
patients.
Chapter 6
112
References
1. Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus - a genetically
programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;
334:777-83. 
2. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to
treatment with oral antidiabetic agents in non-insulin-dependent diabetes mellitus. Diabetes
Care 1986; 9:129-33.
3. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998; 352:837-53. 
4. Groop L, Schalin C, Franssila-Kallunki A, Widén E, Ekstrand A, Eriksson J. Characteristics
of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy.
Am J Med 1989; 87:183-90. 
5. Turner RC, Cul CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea,
metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for
multiple therapies. JAMA 1999; 281:2005-12.
6. Johnson SB. Methodological issues in diabetes research. Measuring adherence. Diabetes Care
1992; 15:1658-67.
7. Skaer TL, Sclar DA, Markowski DJ, Won JKH. Effect of value-added utilities on
prescription refill compliance and Medicaid health care expenditures - a study of patients
with non insulin dependent diabetes mellitus. J Clin Pharm Ther 1993; 18:295-9.  
8. Urquhart J. Patient non-compliance with drug regimens. measurement, clinical correlates,
economic impact. Eur Heart J 1996; 17(Suppl A):8-15.
9. Paes AHP, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci
1998; 20:73-7.
10. Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic
agents in a drug-insured U.S. Population. Diabetes Care 2001; 24:1411-5. 
11. Venturini F, Nichol MB, Sung JCY, Bailey KL, Cody M, McCombs JS. Compliance with
sulfonylureas in a health maintenance organization: a pharmacy-record based study. Ann
Pharmacother 1999; 33: 281-8. 
12. Paes AHP, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance.
Diabetes Care 1997; 20:1512-7.
13. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment
using centralized pharmacy records. Med Care 1988; 26: 814-23. 
14. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records:
methods, validity, and applications. J Clin Epidemiol 1997; 50:105-16. 
15. Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use,
nonadherence, and mortality in a defined population with type 2 diabetes. Clin Ther 1999;
21:1045-57.
16. Herings RMC, Bakker A, Stricker BHC, Nap G. Pharmaco-morbidity linkage: a feasibility
study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community
Health 1992; 46: 136-40. 
17. Herings RMC. PHARMO; a record linkage system for postmarketing surveillance of
prescription drugs in the Netherlands [dissertation]. Utrecht: Utrecht University, 1993. 
18. Anonymous. Nordic Statistics on Medicines 1981-1983. Part II. Nordic Drug Index with
Classification and Defined Daily Doses. Uppsala, Nordic Counsil on Medicines, 1985. 
Refill compliance and switching to insulin
113
19. Krall R. Interactions of compliance and patient safety. In: Patient compliance in medical
practice and clinical trials. New York: Raven Press 1991:19-25.
20. Urquhart J, de Klerk E. Contending paradigms for the interpretation of data on patient
compliance with therapeutic drug regimens. Stat Med 1998; 17:251-67. 
21. Korff von M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy
data. J Clin Epidemiol 1992; 45:197-203. 
22. Johnson RE, Hornbrook MC, Nichols GA. Replicating the chronic disease score (CDS)
from automated pharmacy data. J Clin Epidemiol 1994; 47:1191-9. 
23. Clark DO, Korff von M, Saunders K, Baluch WM, Simon GE. A Chronic Disease Score
with empirically derived weights. Med Care 1995; 33:783-95. 
24. EGRET for Windows. Cambridge MA, 1999. 
25. Evans JMM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents in type 2
iabetes: is this a predictor of insulin requirement ?[abstract] Diabetologia 2001; 44(suppl1):A36.
26. Lau HS, De Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug
exposure assessment. J Clin Epidemiol 1997; 50:619-25. 
27. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance.
Am J Hosp Pharm 1992; 49:1691-6. 
28. Beardon PHG, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary
non-compliance with prescribed medication in primary care. BMJ 1993; 307:846-8.
29. Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent
research. Clin Pharmacokinet 1994; 27:202-15. 
30. Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea
pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and
race. Diabetes Educ 1999; 25: 531-8. 
31. Kavanagh DJ, Gooley S, Wilson PH. Prediction of adherence and control in diabetes. J Behav
Med 1993; 16: 509-22.

CHAPTER 7
Antipsychotic Drugs May Worsen 
Metabolic Control in Type 2 Diabetes
Mellitus Patients

Antipsychotics and worsening of metabolic control
117
Abstract
Aim - Several studies have indicated that type 2 diabetes mellitus is more common
among schizophrenic patients than in the general population. Purpose of the
present study was to assess the association between the use of antipsychotic drugs
and alterations of glycemic control. 
Methods - In this cohort study, newly diagnosed patients with type 2 diabetes were
selected from the PHARMO Record Linkage System, comprising pharmacy
records for all 320,000 residents of six Dutch cities. In total, 2,585 patients with
type 2 diabetes were identified as incident oral hypoglycemic agents users between
1991-1997 and had at least two years medication history after diagnosis. Switching
from oral hypoglycemic agents to insulin therapy was considered a proxy for
deterioration of beta-cell function. We compared the incidence of switching
between users of antipsychotic drugs and non-users by performing a Cox’s
proportional hazards model analysis.
Results - Two years after diagnosis we found an increased risk for switching to
insulin therapy for users of antipsychotics compared to non-users; the relative
hazard (hazard ratio, HR) was 2.0 (CI95%: 1.2 – 3.3), which did not change after
adjustment for potential confounders. The risk decreased in the subsequent years
after diagnosis. 
Conclusion - It seems that use of antipsychotics in type 2 diabetes mellitus is
associated with switching to insulin therapy (i.e. ‘secondary failure’), especially in
the first two years of the disease.
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Introduction
Several studies indicate that type 2 diabetes mellitus, impaired glucose tolerance,
and insulin resistance are more common among patients with psychiatric disorders,
such as major mood disorders and schizophrenia, than among the general
population.1-3 As type 2 diabetes advances, secondary failure of oral hypoglycemic
therapy develops as a consequence of progressive loss of beta-cell function and
worsening of insulin resistance caused by persistent hyperglycemia and possible
development of drug resistance.4 
In recent years, case reports have been published describing the emergence
of de novo onset of diabetes or worsening of previously well-controlled diabetes
after the start of treatment with atypical antipsychotics.5-10 Those ‘novel’
antipsychotics are called atypical for their relative lack of the extrapyramidal side
effects typical of older, mostly higher dosed antipsychotics.11, 12 Furthermore,
already decades ago it has been reported that conventional neuroleptics,
chlorpromazine in particular, may also alter glucose-insulin homeostasis13, 14 and
lead to new cases of diabetes mellitus.15 
The present study deals with the possible relationship between the use of
antipsychotic drugs and worsening of glycemic control in patients with type 2
diabetes mellitus. Switching from oral hypoglycemic agents to insulin therapy is
considered a proxy for deterioration of metabolic control. Therefore, we compared
‘switchers’ and ‘non-switchers’ with respect to antipsychotic drug use during a
period following diagnosis of type 2 diabetes mellitus.
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Patients and Methods
Data source
The PHARMO Record Linkage System (PHARMO RLS) was used as data source
for this study, comprising pharmacy dispensing records of all community-dwelling
residents of six Dutch cities, counting for more than 450,000 patients histories,
from 1985 to present.16, 17 Drugs were coded according to the Anatomical Therapeutic
Chemical (ATC) Classification.18 Because in the Dutch health care system ambulatory
patients are usually designated a single pharmacy to fill their prescriptions
independent of prescriber, virtually complete data are available for each subject.
These data include sex, date of birth, drug names with ATC codes, dispensing date,
total supply, prescribed dosage regimen, and prescriber. Pharmacy data from
January 1991 to June 1999 were obtained for this study, comprising about 320,000
patient histories.
Study subjects
In this cohort study, incident patients with type 2 diabetes mellitus were defined as
subjects starting their first oral hypoglycemic treatment (ATC code A10B) between
1991 and 1997. Patients were eligible for inclusion if they received no
hypoglycemic medication (tablets or insulin) during 180 days (half a year) preceding
the date of starting oral hypoglycemic agent use. Furthermore, patients were only
included if they were dispensed at least two consecutive prescriptions of oral
hypoglycemic agents. Subsequently, we excluded subjects who switched to insulin
within 3 months (90 days) after their first prescription of a hypoglycemic agent
(’primary failure’).
Study design
We performed a follow-up study in a subcohort of patients who had at least two
years (730 days) of medication history after diagnosis, i.e. first prescription of an
oral hypoglycemic agent. Exposure was defined as the usage of antipsychotic drugs
(i.e. ‘any use’), ATC group N05A (excluding lithium, N05AN), in the two years
after the first use of an oral hypoglycemic agent. The event of interest was defined
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by switching from oral hypoglycemic agents to insulin therapy (ATC code A10A)
with or without continuation of oral hypoglycemic medication. We compared the
incidences of switching to insulin therapy between users of antipsychotic drugs and
non-users. Atypical antipsychotic drugs included risperidone, clozapine,
olanzapine, and quetiapine.19 
Data analysis
For the comparison of continuous variables and categorical variables between
users of antipsychotics and non-users, we used the Student’s t-test and χ2 test,
respectively.
We performed a Cox’s proportional hazards model analysis (variable follow-up) in
the cohort of all incident type 2 diabetic patients who had at least two years of
follow-up. Survival time was from date of first prescription of oral hypoglycemic
agents to the day of switching to insulin therapy. Patients who did not switch were
censored at the date of leaving the pharmacy (i.e. loss to follow-up) or end of study
(July 1999). Use of antipsychotics (dichotomous), age at date of first prescription
of oral hypoglycemic agents (years), gender, and calendar year of diagnosis, were
time-independent variables. 
We adjusted for the use of anticholinergic antiparkinson medication (ATC
group N04A), because a higher rate of switching might be expected in patients
suffering from extrapyramidal side effects. With regard to other potential
confounders, we took into account the use of medication with known side effects
on glucose metabolism: corticosteroids for systemic use (H02), beta-blocking
agents (C07), and thiazides and loop diuretics (C03, except C03D). Because of the
known positive relationship between the prevalence of depressive disorders and
type 2 diabetes20, we also investigated the potential association or interaction
between antipsychotics, switching and antidepressants.
Subsequently, we calculated crude and adjusted relative hazards (hazard
ratios, HR) with the corresponding 95% confidence intervals (CI95%) for switching
to insulin in the users of antipsychotic drugs at several time intervals of follow-up
(two, three, four and five years after diagnosis of diabetes mellitus).
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Results
In total 3,001 patients with newly diagnosed type 2 diabetes mellitus were enrolled
in the study, their demographic characteristics and some data on drug usage are
given in Table 7.1. 
Table 7.1 Basic characteristics of patients with type 2 DM
Variable N = 3,001
Male sex (%) 1472 (49.1%)
Age at index date* (yrs) 63.4 (0.24)
Duration of disease (yrs) 4.0 (0.04)
Total follow-up time (yrs) 9.9 (0.05)
Insulin therapy (%) 603 (20.1%)
Age at switching† (yrs) 62.2 (0.54)
Duration of disease at date of switching† (yrs) 2.8 (0.07)
Drug use during diabetes (%)
Cardiovascular drugs‡ 2298 (76.6%)
Psycholeptic drugs§ 1435 (47.8%)
Antipsychotics|| 248 (8.3%)
Atypical antipsychotics¶ 14 (0.5%)
Lithium 12 (0.4%)
Antidepressive agents 361 (12.0%)
Data are means with standard error of the mean between parentheses or numbers (with
percentages, %)
* date of first prescription of oral hypoglycemic agents
† N = 603 (switchers)
‡ cardiovascular drugs are defined as antithrombotics, cardiacs, diuretics, ß-blockers, calcium
channel blockers, ACE inhibitors, other antihypertensive drugs,  and lipid lowering agents (ATC
codes B01, C01-C03, C07-C10)
§  ATC group N05
|| ATC group N05A (excluding lithium, N05AN)
¶ clozapine, risperidone, olanzapine,  or quetiapine
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Age at diagnosis varied between 18 and 98 years. Among antipsychotic drug users
(‘ever use’), 99 (40%) received only one or two prescriptions, 68 (27%) received 3-
9 prescriptions, 30 (12%) received 10-19 prescriptions, and 51 (21%) received 20
or more prescriptions. In the baseline cohort, within the total follow-up period
only 14 (0.5%) used an atypical antipsychotic drug after the date of first prescribed
oral hypoglycemic agent. Antipsychotic drugs most frequently used were
haloperidol (Haldol, 29%), pipamperone (Dipiperon, 27%), levomepromazine
(Nozinan, 16%), and zuclopenthixol (Cisordinol, 14%).
A total of 2,585 (86%) patients completed two years of follow-up after the
index date (first prescription of oral hypoglycemic agent). They were younger at
diagnosis than the remaining 416 subjects, 62.6 versus 69.0 years (P< 0.001), they
did not significantly differ with respect to gender distribution. These patients were
included in the Cox’s regression analysis. 
Figures 1a – 1d show the ‘insulin free survival’ in antipsychotic users and
non-users during the course of time (exposure definition at two, three, four and
five years after diagnosis, respectively). For instance, after four years of disease,
well over 20% switched to insulin therapy in both groups. Because primary failure
was an exclusion criterion, the figures show straight regression lines in both groups
during the first three months (i.e. no events). Crude and adjusted HRs are shown
in Table 7.2. Two years after diagnosis we found an significantly increased risk for
switching to insulin therapy for users of antipsychotics compared to non-users; the
hazards were 18.4% and 9.3% respectively, and the crude relative hazard (hazard
ratio, HR) was 2.0 (CI95%: 1.2 – 3.3). In this two-year period, 236 patients (9.1%)
switched to insulin therapy. Adjusted for age at onset and calendar year of first
prescription of an oral hypoglycemic agent, the HR was 2.0 (CI95%: 1.2 – 3.3).
Additionally, we controlled for concomitant medication (see table comments).
Adjustment for differences in gender distribution did not change the results. 
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Figure 7.1 a Cut-off point at 2 years
Figure 7.1 b Cut-off point at 3 years
Figure 1a-1d Switching to insulin therapy by use of antipsychotic drugs after 2, 3, 4, and 5 years
respectively
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Figure 7.1 c Cut-off point at 4 years
Figure 7.1 d Cut-off point at 5 years
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First two years after diagnosis
Subsequently, we singled out the two-year period after diagnosis. We investigated
the degree of continuation of oral hypoglycemic medication after the start of
insulin therapy (i.e. combination therapy) in both groups.  In non-users of
antipsychotics, the oral therapy was continued in about half of the patients (49%),
while in users of antipsychotics only 4 out of 16 switchers (25%) were on
combined medication regimen. The odds ratio for continuation of oral therapy
after switch was 0.4 (CI95%: 0.1 – 1.1), thus borderline significant (p= 0.06). 
Of the 236 switchers, 14 (7.0%) used antipsychotics during the last two
years, compared to 77 (3.3%) of the patients who continued oral hypoglycemic
therapy (OR 2.2, CI95%: 1.2 – 4.0). No switch to insulin therapy was seen in any of
the 6 patients who used atypical antipsychotic drugs. 
Use of antipsychotics was strongly associated with use of antidepressants, in users
of antipsychotics the prevalence of antidepressant use was 34% versus 7% in non-
users (OR 7.5, CI95%: 4.8 – 11.9). After additional adjustment for use of
antidepressants, the relationship was still statistically significant (Table 7.2).
Table 7.2 Crude and adjusted hazard ratios (HRcrude and HRadj) at different time intervals
since diagnosis of DM
Time since diagnosis HRcrude HRadj* HRadj†
2 years 2.0 [1.2-3.3] 2.0 [1.2-3.3] 1.7 [1.0-3.0]
3 years 1.2 [0.8-2.0] 1.3 [0.8-2.1] 1.2 [0.8-2.0]
4 years 0.9 [0.6-1.4] 1.0 [0.7-1.6] 1.0 [0.7-1.6]
5 years 0.9 [0.6-1.3] 1.0 [0.7-1.4] 1.0 [0.7-1.6]
95% Confidence intervals between square brackets
* Adjusted for age at onset and calendar of diagnosis
† Additional adjustment for use of ß-blocking agents, diuretics (thiazides and loop-),
antiparkinson drugs, antidepressants, and corticosteroids for systemic use
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Finally, when we compared the risk of switching to insulin therapy over the total
follow-up period between users and non-users of antipsychotics in the first two
years after the onset of diabetes, the HR was 1.6 (CI95%: 1.1 – 2.4). 
Discussion
In our study, the use of antipsychotic drugs in type 2 diabetes mellitus was
associated with a higher rate of switching to insulin therapy (i.e. ‘secondary
failure’), especially in the first two years of the disease. This present study strongly
indicates that antipsychotic drugs can not only induce diabetes but also cause
worsening of glycemic control in patients with already known type 2 diabetes.
In type 2 diabetes the primary underlying defect is probably insulin
resistance, with an early phase of normal plasma glucose levels maintained by
compensatory hyperinsulinemia. The failure to maintain this compensatory
hyperinsulinemia eventually results in loss of glycemic control and development of
clinical diabetes. Many studies have reported that diabetes, impaired glucose
tolerance, and insulin resistance are more common among patients with
schizophrenia and other mental illnesses than among the general population.1-3, 9, 21
For instance, Mukherjee and colleagues found a 15.8% overall prevalence of
diabetes among schizophrenic patients, this prevalence is considerably higher than
reported from epidemiological surveys in the general population.3 Therefore, the
possibility remains that diabetes in schizophrenia may result from the use of
neuroleptics, rather than the psychiatric disorder itself.22 Although the exact
mechanism of antipsychotic induced diabetes remains obscure, studies by
Ardizzone et al suggest that atypical drugs may block glucose accumulation directly
at the level of the glucose transporter protein in cells derived both from peripheral
and brain tissue.23
Some limitations of this study need to be addressed, notably the lack of
information on important patient factors that predict severity or prognosis of
disease, like body mass index, lipids, smoking habits, HbA1c, prevalence of diabetic
complications, and blood pressure. So the results could be confounded by one of
these factors, without the possibility to correct for it. Therefore, differences in
switching to insulin therapy may to some extent be explained by metabolic
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differences. For instance, type 2 diabetes mellitus is strongly and consistently
associated with overweight and obesity.  Moreover, weight gain is a well-known
side effect of antipsychotic drug use24, 25, so maybe the weight gain is partly
responsible for the worsening of metabolic control rather than the drug itself.26
Although we cannot examine the possible etiologic causal explanations, this does
not weaken the found association between antipsychotic drug use and worsening
of glycemic control.
Furthermore, it is important to mention that we studied an elderly
population with type 2 diabetes in an outpatient setting. Data were obtained from
community pharmacies so patients living in nursing homes, psychiatric institutes,
and mental clinics were not included. Elderly patients have various medical
grounds for using antipsychotic drugs, for instance: (nocturnal) agitation, the
beginnings of dementia, acute psychosis, delirium, bipolar disorder, or
schizophrenia. Unfortunately, we had no information on the indication for which
the antipsychotic drugs were prescribed. So, we could not link psychiatric
diagnoses to switching to insulin therapy directly.
Antipsychotic drugs can be classified, based on their liabilities to induce
extrapyramidal side effects (EPS), into two main categories: typical antipsychotics,
which are often associated with EPS of both acute and chronic nature and atypical
antipsychotics, which cause a significant lower incidence of EPS.11 In contrast to
current belief, we found no difference between atypical and conventional
antipsychotic drugs with regard to worsening of glycemic control, but the ‘novel’
drugs were rarely prescribed and no event of interest was observed in the group of
atypical antipsychotic drug users.
We propose that the observed worsening of metabolic control is probably
due to pancreatic beta-cell toxicity of antipsychotic drugs. First, the deterioration
appears in an early stage of the disease, which suggests that antipsychotic drugs
have a quite immediate effect in susceptible subjects. The fact that two, three, four,
and five years after the diagnosis of diabetes the corresponding risk for switching
in users of antipsychotics compared to non-users changed from 2.0 through 1.2
into 0.9, indicates an acute effect that diminishes in the course of time. This is
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strongly in favor of beta-cell toxicity rather than deterioration of insulin resistance,
which would cause a more gradual decline in beta-cell function.
Secondly, after the switch to insulin therapy only 25% of the antipsychotic
users continued their oral hypoglycemic therapy, which is half the prevalence of
combination therapy in non-users. Since the mechanism of action of all oral
hypoglycemic agents to a great extent depends on the residual activity of the beta-
cell, oral therapy will be ineffective if beta-cell toxicity is the case. 
In conclusion, our study suggests that antipsychotics, besides already known
diabetogenic effects, can lead to fast deterioration of glycemic control, probably
due to beta-cell toxicity. Although many aspects of this relation remain unclear and
uncertain, we believe that glycemic control should be monitored more closely in
these patients.
Antipsychotics and worsening of metabolic control
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Introduction
This thesis started with a discussion on the gradually and frequently progressive
nature of the disease course of type 2 diabetes mellitus, previously named Non-
Insulin-Dependent Diabetes Mellitus or adult-onset diabetes. The disease of
interest in this thesis is a metabolic disorder characterized by the combination of
resistance to the action of insulin and an inadequate compensatory insulin
secretory response of the pancreatic β-cell.1 Biochemical onset invariably precedes
clinical diagnosis, and the pancreatic β-cell function and insulin secretory remaining
capacity in newly diagnosed patients will differ. Disease control and response to
therapy are traditionally evaluated by assessing HbA1c levels. Since the last few
years also other risk factors such as blood pressure and serum cholesterol levels are
determined. These risk factors reflect intrinsic disease severity as modified by
patient self-care behavior and clinical management.
Glycemic control deteriorates further with time as complications ensue,
accompanied by progressive requirements for higher doses of hypoglycemic
agents.2, 3 Moreover, many patients end up in a phase where insulin therapy is
needed to achieve adequate glycemic control. Hub-and-spokes patterns of patients
switching between different treatment scenarios are rather the rule than the
exception. Some selected, but typical courses of diabetes in general practice and
response to therapy strategies over time are depicted on the facing page (Figure
8.1).
In this thesis, treatment courses of type 2 diabetes as been depicted in Figure 8.1
have been assessed with regard to determinants and effects of switching between
different available glucose lowering treatment strategies. We will discuss in this
chapter the headlines of our findings, will put them in the perspective of further
research and will conclude with some comments on the prospects of UDES. We
will address the research value and accessibility of routinely recorded data in health
care for scientific purposes.
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Figure 8.1 (cases selected from the source population as described in Chapter 2) shows
typical glycemic control (HbA1c, %) in three female patients with type 2 diabetes mellitus,
following different glucose lowering treatment strategies. 
Patient A was 57.9 years old (weight 84 kg, height unknown) at onset of diabetes and
started immediately with oral therapy, notably tolbutamide. She was treated for
dyslipidemia with pravastatin 20 mg once daily. Fasting and non-fasting glucose levels at
diagnosis were 9.0 and 20.2 mmol/l. After almost three and a half-year (black asterisk)
she switched over to insulin therapy. Patient B, 66.9 years old, with a body mass index of
23.3 kg/m2 and fasting- and non-fasting blood glucose levels of 6.8 and 11.7,
respectively, at diagnosis. She had hypercholesterolemia, treated with fluvastatin 40 mg
daily, and a cerebrovascular accident in her medical history. She achieved a maximum
weight loss of 5 kg (BMI 21.6 kg/m2) and remained stable at a weight of 57 kg (BMI 22.5
kg/m2). This patient had a mean HbA1c value of 6.2% and showed excellent glycemic
control on dietary treatment only. Patient C, 54.3 years old, with untreated hypertension,
had fasting- and non-fasting glucose levels of 10.8 and 18.8 mmol/l when diagnosed with
type 2 diabetes. She started with lifestyle changes but after a good initial response,
illustrated by decreasing HbA1c, glycemic control deteriorated. She gained weight during
course of the disease, increasing from 65 (BMI 24.5 kg/m2) to 67 (25.2 kg/m2) kg. Well
over three years since diagnosis oral drug treatment was initiated with glicazide (white
asterisk).
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Glucose lowering therapy in general practice: initiation and
switching
The first-line therapy modality for type 2 diabetes includes an optimal diet with
appropriate weight reduction and exercise accompanied by patient education and
self-management. Only when these measures fail to restore adequate glycemic
control after a run-in period of at least three months, pharmacologic treatment
should be considered.4, 5 However, in a reaction coming from internal medicine on
the Dutch GP guidelines, the reviewer argued in favor of earlier control and
consideration of the height of the blood glucose level.6
Pharmacological treatment of diabetes may be no more than a surrogate for
successful weight loss, the only strategy that offers the prospect of cure.7, 8 In obese
patients with type 2 diabetes, weight loss of 10 kg can achieve greater reductions in
HbA1c and fasting glucose than treatment with metformin, and improves control
of lipid and blood pressure without the need for additional drug treatment.9 
However, although diet and exercise can be effective strategies over the short-
term, only a few patients obtain substantial long-term benefit.
Early in the course of the disease, insulin resistance and hyperinsulinemia
characterize diabetes. But as the disease progresses and insulin deficiency becomes
the central issue, it may be to late for weight loss to be helpful. In fact, we doubt
whether patients who remain on dietary treatment for years and have adequate and
stable glycemic control merit the diagnosis ‘type 2 diabetes mellitus’, or rather just
have relative insulin resistance due to overweight or obesity. 
As shown in Chapter 2, a small but substantial part of newly diagnosed type 2
diabetes patients remains on diet only while achieving good glycemic control. This
shows that indeed a small proportion of patients is able to ‘cure’ their diabetes by
their lifestyle changes, weight loss in particular. However, it is also possible that the
diagnosis was made incorrectly. One could question if these patients have been
‘cured’ by their lifestyle changes - weight loss in particular - or if the diagnosis was
incorrect.
At 3 years after diagnosis of diabetes, approximately 50% of patients will need
more than one pharmacological agent because monotherapy does not achieve the
target values of HbA1c and by 9 years approximately 75% of patients will need
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multiple therapies to achieve FPG concentrations of less than 7.8 mmol/l or
HbA1c levels below 7%.2 It is apparent by 9 years after diagnosis that even with a
combination of oral agents a substantial number, possibly the majority, of patients
will need the addition of insulin therapy to obtain an HbA1c level below 7%.2 GPs
should not hesitate too long to take this step, because after initial fear or
reservation of both patients and doctors, metabolic control and treatment
satisfaction increase, while cardiovascular risk decreases.10-12 The UKPDS showed
that in patients with type 2 diabetes, complications of the disease affected quality
of life, whereas therapeutic policies shown to reduce the risk of complications had
no effect on quality of life.13 A Dutch study presented similar results, but besides
complications also insulin therapy and obesity were independently associated with
a lower health-related quality of life.14 In our study in Chapter 2 we showed that
the initial severity of diabetes, assessed by the degree of hyperglycemia, is a major
factor in determining the likelihood of achieving target levels of glycemic control in
the future, regardless of actual glucose lowering treatment.
We found that increased intensity of glucose lowering therapy was
significantly associated with poorer glycemic control, higher body weight and
increased prevalence of hypertension (Chapter 3). Despite further deterioration of
glycemic control with intensified glucose lowering treatment, control of other
metabolic risk factors remained stable, probably due to increased prescribing of
cardiovascular drug therapy. These findings are consistent with the results from a
review on glycemic control and cardiovascular disease by Wild et al. They
concluded that control of hypertension and hyperlipidemia are important to reduce
risk of cardiovascular disease in people with diabetes and may be more easily
achieved than tight glycemic control.15 In the near future, hopefully more insight
regarding the association between blood pressure and glucose lowering therapy and
the development of micro-and macrovascoular outcomes in type 2 diabetic
patients will be provided by results from the ADVANCE study.16 ADVANCE is
designed to provide reliable evidence on the balance of benefits and risks
conferred by blood pressure lowering therapy and intensive glucose control
therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose
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concentrations. The primary outcomes are, first, the composite of non-fatal stroke,
non-fatal myocardial infarction or cardiovascular death and, second, the composite
of new or worsening nephropathy or diabetic eye disease. 
It is possible that secondary failure of oral hypoglycemic drugs with subsequent
insulin requirement may, in fact, be due to poor adherence rather than to β-cell
exhaustion. In our study (Chapter 6) we found a relatively high refill prescription
rate of 97% compared to other studies. Part of this difference can be explained by
difference with regard to methodology in calculation of refill compliance. For
instance, in the study by Donnan et al, the previous prescription was censored at
the start of the new prescription, if a subsequent prescription was refilled before
the end of a previous prescription, possibly leading to an underestimation of refill
compliance.17 Although we were unable to proof a relationship between
noncompliance – as measured by refill compliance rates - and secondary failure, we
still believe that poor adherence is a major obstacle to the benefit of complex drug
regimens in the treatment of type 2 diabetes.18, 19 But other variables like
comorbidity and disease related factors seem to play a more important role in
switching to insulin therapy (Chapter 5, Chapter 7).
Subtypes in type 2 diabetes mellitus: individualized treatment
strategies based on antibodies or clinical features?
Some patients who present with a clinical picture consistent with type 2 diabetes
have autoantibodies similar to those found in type 1 diabetes, and may masquerade
as type 2 diabetes if antibody determinants are not made.20-22 Islet cell
autoimmunity, which is characteristic of type 1 diabetes, appears in fact to be
present in up to 10-15% of subjects diagnosed clinically with type 2 diabetes. In
the UKPDS, it was reported that in patients diagnosed with type 2 diabetes, the
presence of autoantibodies to the enzyme glutamic acid decarboxylase (GAD) and
cytoplasmic islet cell antibodies (ICA) were a predictor of insulin requirement. In
addition, Syed and colleagues found in a subset of type 2 diabetes patients a
pronounced activation of acute phase response that seems to be associated with
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islet cell autoimmunity.23 They proposed the identification of a subgroup of type 2
diabetes patients by using autoantibody as well as inflammatory markers.
Individualized therapeutic strategies could potentially be instituted sufficiently early
in course of the disease and most likely delay the onset of insulin requirement and
the complications related with hyperglycemia.23
We strongly debate the feasibility of this approach in daily general practice. These
laboratory tests are very costly and time-consuming. Furthermore, cost-
effectiveness of this secondary screening method is unclear.
As shown in Chapter 2 and Chapter 4, one can also distinguish different
groups of patients based on response to glucose lowering therapy or
antihypertensive treatment.
Indeed, we would favor a more practical approach based on response to glucose
lowering therapy and phenotypical characteristics (e.g. lean versus obese, young
versus old) of the patient.21, 22 In the randomization process of the UKPDS,
roughly three types of type 2 diabetic patients were distinguished.2 First of all, the
primary diet failure group, consisting patients with a fasting plasma glucose (FPG)
concentration higher than 15 mmol/l or continued symtoms due to hyperglycemia.
Secondly, asymptomatic patients with FPG concentrations of 6 to 15 mmol/l
during the run-in period of three months of lifestyle recommendation only (mainly
dietary advice). The last group, termed diet satisfactory, maintained on diet alone
and achieved FPG values below 6 mmol/l and developed no symptoms due to
hyperglycemia. 
When we apply this categorization to our study, the different subtypes are
represented by patient A, C, and B respectively in Figure 8.1. For the primary diet
failure group (patient A), it seems very important to intensify drug treatment in
time, especially timely addition of insulin to the therapeutic regimen.12, 24
Unfortunately, our results (Chapter 5) suggested that insulin therapy is often
started after the development of diabetic complications and other comorbidity; in
other words, ‘one locks the stable after the horse has bolted’. Patients achieving
excellent glycemic control for a long time on dietary treatment only (patient B),
were excluded form the analysis in the UKPDS.2 However, we believe this to be an
intriguing patient group that deserves further research (Chapter 2). The ‘normal’
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type 2 diabetic patient is represented by patient C, who after an initial good
response to lifestyle intervention needs pharmacological treatment due to
deterioration of the β-cell function. Ultimately, most of these patients will require
(addition of) insulin.2
Switching means trouble?
Although overall treatment satisfaction in Dutch patients with type 2 diabetes is
very high14, patients with diagnosed diabetes mellitus type 2 are not being managed
optimally (Chapter 3, Chapter 5).25, 26 In the future, the treatment for diabetes
mellitus type 2 must be directed towards the development of treatments tailored to
meet the individual patient's needs.27, 28 We should set targets that are reasonable
for individual patients. These targets will be evidence based in so far as they will be
derived from the findings of research studies, but they cannot in reality seek to
achieve results attained in such artificial circumstances. 
Switching indicates trouble because patients who require multiple therapies
shortly following diagnosis have a worse prognosis with regard to future glycemic
control, accompanied by more (cardiovascular) comorbidity and comedication.
Concerning daily practice, the emphasis lays on stepping in time with the disease.
Ultimately, efforts to achieve the HbA1c target of 7% will require at least 50% of
patients with type 2 diabetes to be treated with insulin, with major resource
implications as well as practical challenges.28 Optimal diabetes treatment is not only
switching to oral or insulin therapy, but also adding blood pressure lowering and
lipid lowering drugs in time.
Although control of blood glucose levels remains the cornerstone of the
treatment of type 2 diabetes mellitus, the high prevalence of concomitant diseases
emphasizes that pharmacotherapy in type 2 diabetes mellitus should not be limited
solely to this objective. Polypharmacy may be unavoidable. Results from
randomized clinical trials indicate that drug treatment of cardiovascular risk factors,
such as hypertension and hyperlipidemia, substantially reduce the risk of
cardiovascular diseases.29-32 In the Heart Protection Study on cholesterol lowering
therapy in high-risk individuals (including diabetes), allocation to 40 mg simvastatin
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daily reduced the rates of myocardial infarction, stroke and revascularization by
about one-quarter.32 Therefore, treatment of cardiovascular morbidity and risk
factors should be another key factor in the treatment of type 2 diabetes mellitus.33
Given the cardiovascular risk profile of type 2 diabetes, up to 10% of patients
could require two or three hypoglycemic agents (ultimately including insulin), at
least three antihypertensive agents, two hypolipidemic agents, and aspirin.28 
From a practical point of view, it might be expected that a simple treatment
regimen such as once daily therapy would improve adherence, as a study of 91
patients treated with sulfonylureas alone demonstrated, using MEMS devices.18
The development of combination tablets by the pharmaceutical industry seems to
be an important goal for better prognosis and effective prevention of
complications in type 2 diabetes.28 Pharmacotherapy of type 2 diabetes is a
complicated task and next steps in management of glycemic control may partly be
based on drug history data. Therefore, teamwork between physicians, pharmacist
and the diabetic patients themselves is needed.
UDES: where are we now and future prospects
The Utrecht Diabetes Epidemiology Studies (UDES) were initiated to study the
effectiveness of diabetes care and drug outcomes (i.e. glycemic control, micro- and
macrovascular complications), to identify the management of risk factors (i.e.
cardiovascular diseases, pregnancy, psychiatric disorders, poor compliance), and to
study effectiveness of innovation in insulin therapy (fast-acting insulin analogues,
computed insulin pen). For the studies, a database comprising pharmacy, hospital
admission and general practitioner data was established to gain more insight in the
treatment of diabetes mellitus in daily clinical practice.
A major limitation of the use of observational studies in the assessment of
intended effects of treatment is confounding by (contra-)indication for treatment.34,
35 The prescribing of drugs to patients by physicians is by definition not random.
For instance, because oral hypoglycemic agents and insulin are generally added as a
result of worsening metabolic control, it seems logical that a strong association
exists between required intensity of therapy and HbA1c level. Thus, in contrast to
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randomized clinical trials, prognoses of differently treated patients are usually not
comparable, resulting in a biased estimate of the treatment effect. Epidemiological
methods such as matching, restriction and multivariate adjustment can be used to
control for confounding. Other methods, such as the use of propensity scores,
may help to improve the validity of estimates of effectiveness of drug treatments in
observational studies.36-38
In the future, research opportunities will be improved within the framework
of UDES by not only linking pharmacy, hospital admission and general practice
data, but also including laboratory data. Linkage of routine data deriving from
different disciplines of health care has great potential for future epidemiological
studies and could make an important contribution to the improvement of the
quality of diabetes care in general and also makes identification of adverse effects
possible.  Concerning privacy issues in medical research, weighing of ethical ‘costs’
and ‘benefits’ is an essential and productive additional perspective in the design
and conduct of epidemiological studies.39
UDES has the potential to become one of the well-established research databases
comprising routinely collected data (such as the General Practice Research
Database40, 41, MEMO/DARTS42). An important added value of the UDES
database could be the high representativeness of daily clinical care. In fact, even
with regard to data-collection, there were no interventions performed at all. 
With regard to future orientation, validation and assessment of the quality of the
database are important and also necessary issues.43 For instance, in the DARTS
study, a detailed manual study of relevant records for patients registered with a
random sample of eight general practices allowed for validation of the case
ascertainment.42  In view of the quality and validation of the GPRD, only data
meeting the minimum standards are added to the research database. Practices that
fail to meet the required standards are removed from the database. There have also
been several validation studies of the GPRD, confirming that the quality and
completeness of the computerized recorded data is high.40, 43  
Considering validation of the UDES database, we would suggest clinical
examination in combination with laboratory testing in a random sample of patients
to confirm the medical history of type 2 diabetes, instead of (manual) medical
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record searching. Additionally, by this approach one will gain an insight the
proportion of possibly cured or incorrectly diagnosed patients.
Final considerations
In conclusion, based on the studies described in this thesis, the following
recommendations for clinical practice and research are given. As a main strategy in
diabetes care we would favor physicians to perform distinct individualized
treatment strategies in type 2 diabetes mellitus, based on the subgroups defined by
clinical characteristics rather than pathophysiological differences. For instance, the
uniform approach of a three-month run-in period of dietary treatment, as
recommended in the Dutch General Practitioners’ guidelines, seems too long in
some patients (with primary failure to diet therapy). 
Practical recommendations should be based on initial response to glucose
lowering therapy and severity of diabetes at diagnosis. Furthermore, validation of
the UDES databases is needed in the future, we would recommend clinical
examinations in addition to medical record searching.
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Diabetes mellitus is defined by chronically increased blood glucose levels, e.g.
‘hyperglycemia’. Patients with type 2 diabetes are characterized by defects in both
insulin secretion and insulin action due to insulin resistance and failure of the
pancreatic beta-cell function. Reduction of hyperglycemia aims to prevent micro-
and/or macrovascular complications in patients with type 2 diabetes, so glucose
lowering therapy is the cornerstone of the management of type 2 diabetic patients.
The reality of daily clinical practice may not cohere with the results from
randomized clinical trials. Studying determinants of glucose lowering drug use may
help to explore the gap between clinical practice and evidence. In this thesis, the
treatment of type 2 diabetes mellitus has been assessed with regard to determinants
and effects of different glucose lowering strategies. 
The first-line therapy modality for type 2 diabetes includes an optimal diet with
weight reduction and exercise accompanied by patient education and self-
management. According to the Dutch general practitioners’ guidelines for type 2
diabetes care, pharmacological treatment has to be considered if target levels of
glycemic control are not achieved after a dietary period of at least three months.
Little is known about the clinical grounds on which the general practitioners make
the decision to initiate pharmacological therapy and the perspectives of these
patients with respect to future glycemic control. In Chapter 2 we showed that the
initial severity of diabetes, assessed by the degree of hyperglycemia at diagnosis, is
the major factor in determining the time to start drug treatment and the likelihood
of achieving target levels of glycemic control in the future, independent of glucose
lowering therapy. Remarkably, a small proportion of the patients remained on
dietary treatment only for a long time and still achieved good glycemic control
(HbA1c < 7.0 %).
In Chapter 3 and Chapter 4, we studied determinants and effects of different
strategies in glucose lowering therapy. Firstly, we assessed whether more intensive
glucose lowering therapy resulted in adequate glycemic control. Increased intensity
of hypoglycemic therapy was significantly associated with poorer glycemic control,
higher body weight and increased prevalence of hypertension. Despite
deterioration of glycemic control with intensified treatment, control of other
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metabolic risk factors such as high blood pressure and cholesterol remained stable,
probably due to increased prescribing of cardiovascular drugs (Chapter 3).
Furthermore, when focusing on the association between antihypertensive
medication, blood pressure and glycemic control (Chapter 4), it was shown that
patients using antihypertensives had better glycemic control, notably lower HbA1c
levels, and increased body weight. We believe that patients with diabetes mellitus
who do not use antihypertensive medication comprise a subgroup of patients with
predominantly beta-cell failure.
As type 2 diabetes mellitus advances, secondary failure develops as a consequence
of progressive loss of beta-cell function and worsening of insulin resistance caused
by persistent hyperglycemia and possible development of drug resistance. If oral
treatment initially works but later fails, patients need to switch over to insulin
therapy. There is little data on factors that are associated with this therapeutic
switch. We compared switchers and non-switchers with respect to demographic
characteristics, metabolic control, comorbidity, co-medication, and compliance to
their oral drug regimen.
In a population of 152 type 2 diabetes mellitus patients in Almere (Chapter 5), it
was found that patients who switched to insulin were younger at diagnosis, had
worse metabolic control and suffered from more health problems besides diabetes.
Especially cardiovascular disease was more frequently present among switchers,
77.4% versus 52.9% (odds ratio (OR) 3.1; 95% confidence interval (CI95%): 1.2-
7.6).  The Dutch PHARMO Record Linkage System was used as data source for
the studies performed in Chapter 6 and Chapter 7, The PHARMO RLS
comprises pharmacy dispensing records linked to hospital admission data of all
community-dwelling residents of eight cities (N~ 450,000) from 1985 onwards.
Chapter 6 describes the results of a matched case-control study; we compared
patients who switched to insulin (cases) with patients still on oral therapy on the
index date (controls) with respect to refill compliance. ‘Compliance’ has been
defined as an attempt by patients to take their medication each day as prescribed.
This was assessed by calculating the extent to which the patient’s actual history of
drug administration corresponds to the prescribed regimen. The overall
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compliance rate did not differ significantly between cases and controls, the
adjusted OR was 1.3 (CI95% 0.6-2.8). So, we were unable to confirm the hypothesis
that noncompliance with treatment is more prevalent in patients with secondary
failure. In conclusion, cases suffered more often from severe comorbidity (assessed
by the Chronic Disease Score) and used a higher number of oral hypoglycemic
agents and concomitant non-diabetic drugs. Other comorbidity and disease-related
factors that play a role in switching to insulin therapy are illustrated in Chapter 5
and Chapter 7.
Because several studies indicated that type 2 diabetes is more common among
schizophrenic patients than in the general population, we examined the association
between antipsychotic drugs and alterations of glycemic control (Chapter 7). We
considered switching from oral hypoglycemic agents to insulin therapy a proxy for
deterioration of beta-cell function. Two years after diagnosis we found an
increased risk for switching to insulin therapy for those patients using
antipsychotics compared to non-users; the hazard ratio (HR) was 2.0 (CI95%: 1.2-
3.3). This risk decreased in subsequent years following diagnosis.
The thesis was concluded in Chapter 8, where the results of our studies are
discussed with a focus on optimizing diabetes treatment strategies based on
different subgroups of type 2 diabetic patients that are easily identified based on
clinical characteristics rather than pathophysiology. Clinical practice should depend
on initial response to glucose lowering therapy and severity of diabetes at
diagnosis. Roughly, three types of type 2 diabetic patients were distinguished; the
primary diet failure group, the diet satisfactory group and an intermediate group of
‘normal’ type 2 diabetes patients. Furthermore, we stressed the importance of
validation of the UDES database concerning future research purposes.
In conclusion, the studies presented in this thesis show that combining data that
are routinely collected in clinical practice can give more insight into treatment of
type 2 diabetes. It is important for physicians to set targets that are reasonable for
individual patients, the emphasis lays on stepping in time with the disease and the
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need for constant reassessment of the diabetic patient accompanied by appropriate
therapeutic adjustments. Pharmacotherapy of type 2 diabetes is a complicated task
and next steps in management of glycemic control may be partly based on drug
history data. Therefore, teamwork between physicians, pharmacists and the
diabetic patients themselves is needed.
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De aandoening diabetes mellitus wordt gekenmerkt door een chronisch verhoogd
glucosegehalte in het bloed, oftewel ‘hyperglykemie’. Karakteriserend voor
patiënten met type 2 diabetes is dat zij lijden aan een defect in zowel de
uitscheiding als de werking van insuline ten gevolge van insulineresistentie en
onvoldoende activiteit van de beta-cel in de alvleesklier. Aangezien verlaging van
het bloedsuikergehalte in belangrijke mate bijdraagt  aan het voorkómen van
microvasculaire (retinopathie, nefropathie, neuropathie) en macrovasculaire
complicaties (myocardinfarct, herseninfarct, perifeer vaatlijden) vormt
glucoseverlagende therapie dé pijler van de behandeling van patiënten met type 2
diabetes.
Mogelijkerwijs stemt de realiteit van de dagelijkse klinische praktijk niet altijd
overeen met resultaten zoals deze zijn gevonden in gerandomiseerde klinische
onderzoeken (randomized clinical trials, RCTs). Het bestuderen van determinanten
van glucoseverlagende therapie kan een goede hulp zijn bij het exploreren en de
overbrugging van de verschillen tussen klinische praktijk en aangetoonde
experimentele studieresultaten.   In dit proefschrift zijn determinanten en effecten
van verschillende bloedsuikerverlagende strategieën in het kader van de
behandeling van type 2 diabetes mellitus bestudeerd. 
De behandelingsmodaliteit van eerste keus bestaat uit een optimaal dieet met
gewichtsreductie en stimulering van de lichamelijke activiteit in combinatie met
patiënteneducatie en zelfsturing. Volgens de type 2 diabetes mellitus
behandelingsstandaard van het Nederlands Huisartsen Genootschap (NHG) moet
medicamenteuze therapie worden overwogen als de glykemische streefwaarden
niet bereikt worden na behandeling met een dieet gedurende tenminste drie
maanden.
Er is weinig bekend omtrent de klinische gronden op basis waarvan huisartsen de
beslissing nemen om te starten met farmacologische therapie en ook de
toekomstige vooruitzichten van deze patiënten wat betreft verdere glykemische
controle zijn onduidelijk.
In Hoofdstuk 2 hebben we aangetoond dat de initiële ernst van de aandoening,
bepaald door de mate van hyperglykemie op het moment dat type 2 diabetes is
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gediagnosticeerd, de belangrijkste factor is aangaande de bepaling van de termijn
tot het starten van medicamenteuze therapie. Tevens hangt de ernst van de
aandoening bij diagnose sterk samen met de waarschijnlijkheid om
glucosestreefwaarden te bereiken in het toekomstige beloop van de ziekte,
onafhankelijk van de gekozen bloedsuikerverlagende therapie. Opvallend is het feit
dat voor een kleine groep patiënten een goede glykemische regulatie (HbA1c<
7.0%) haalbaar was ondanks de exclusieve behandeling met een dieet gedurende
langere tijd.
In Hoofdstuk 3 en Hoofdstuk 4 bestudeerden we determinanten en effecten van
verschillende bloedsuikerverlagende behandelingsstrategieën. Allereerst is bepaald
in hoeverre intensivering van de glucoseverlagende behandeling resulteerde in een
adequate glykemische controle. Een intensievere bloedsuikerverlagende
behandeling was significant geassocieerd met een slechtere glykemische controle,
een hoger lichaamsgewicht en een verhoogde prevalentie van hypertensie.
Ondanks de waargenomen verslechtering van de bloedglucose controle  bij een
intensievere behandeling bleef de controle van andere metabole risicofactoren
zoals hoge bloeddruk en cholesterol stabiel, mogelijk als gevolg van een frequenter
voorschrijven van cardiovasculaire medicatie (Hoofdstuk 3).
Wanneer de relatie tussen bloeddrukverlagende medicatie, bloeddruk en
glykemische regulatie (Hoofdstuk 4) nader onder de loep werd genomen, werd
bovendien aangetoond dat gebruikers van bloeddrukverlagende medicijnen
(antihypertensiva) betere controle van hun bloedglucose bereikten, zij hadden
namelijk lagere HbA1c waarden. Daarnaast hadden zij een hoger lichaamsgewicht
dan de patiënten die geen antihypertensiva kregen voorgeschreven.
Wij denken dat patiënten met diabetes mellitus die geen bloeddrukverlagende
medicatie gebruiken een subgroep vormen bestaande uit patiënten waarbij het falen
van de beta-cel op de voorgrond staat.
Wanneer de ziekte type 2 diabetes mellitus voortschrijdt ontwikkelt zich het
zogenaamd ‘secundair falen’ als gevolg van enerzijds progressief functieverlies van
de beta-cel en een verergering van de insulineresistentie door het voortdurend te
hoge bloedsuikerniveau en de mogelijke ontwikkeling van therapieresistentie ten
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aanzien van orale medicatie anderzijds. Patiënten moeten worden overgezet op een
behandeling met insuline als orale behandeling in eerste instantie voldoende
werkzaam is maar later toch tekortschiet. Weinig is bekend over factoren die
samenhangen met deze therapeutische overschakeling.
In een populatie bestaande uit 152 patiënten met type 2 diabetes mellitus in Almere
(Hoofdstuk 5) toonden we aan dat patiënten die overschakelden naar insuline
therapie (‘switchers’) jonger waren op moment van diagnose, een slechtere
metabole controle hadden en bovendien leden zij  vaker aan andere
gezondheidsproblemen naast diabetes. Switchers presenteerden zich vooral veel
vaker met hart- en vaatziekten, 77,4% versus 52,9% (odds ratio (OR) 3,1; 95%
betrouwbaarheidsinterval (BI): 1,2-7,6). Voor de studies beschreven in Hoofdstuk
6 en Hoofdstuk 7 is als gegevensbron het PHARMO Record Linkage System
(RLS) gebruikt, een Nederlandse database die apotheekgegevens en
ziekenhuisopnames bevat van ongeveer 450.000 patiënten. Hoofdstuk 6 beschrijft
de resultaten van een zogenaamde case-controle studie; waarbij we de mate van
‘refill compliance’ vergeleken in patiënten die overschakelden naar insuline therapie
(zgn. cases) met patiënten die nog steeds orale therapie (tabletten) gebruikten op de
index datum (datum van overschakeling naar insuline in de cases). ‘Refill
compliance’ is een maat voor de therapietrouw (‘compliance’) en is gebaseerd op
apotheekgegevens (afhaaldata van nieuwe medicatie, ‘refill’) in combinatie met
medicatievoorschriften. Een perfecte overeenstemming tussen afleverdata en het
voorgeschreven therapieschema resulteert in een ‘refill compliance’ van 100%.
Cases en controles hadden eenzelfde ziekteduur, zij waren gematched op duur van
de diabetes. De totale compliancegraad verschilde niet significant tussen cases en
controles, de geadjusteerde OR was 1,3 (BI95%: 0,6-2,8). We bleken dus niet in staat
om de hypothese te bevestigen dat een gebrek aan therapietrouw leidt tot een
snellere overschakeling naar insuline therapie. Concluderend leden cases vaker aan
ersntige co-morbiditeit (bepaald aan de hand van de Chronic Disease Score) en zij
gebruikten een hoger aantal orale bloedsuikerverlagende middelen en bijkomende
niet-diabetische medicijnen. In Hoofdstuk 5 en Hoofdstuk 7 worden een aantal
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andere ziektegerelateerde factoren en bijkomende aandoeningen (co-morbiditeit)
beschreven die een rol spelen bij de overschakeling naar insuline therapie.
Aangezien in verscheidene studies aanwijzingen zijn gevonden voor het feit dat
type 2 diabetes vaker voorkomt bij patiënten met schizofrenie dan in de algemene
bevolking hebben we het verband tussen het gebruik van antipsychotica en
veranderingen in de glykemische regulatie onderzocht (Hoofdstuk 7). De
overschakeling van orale bloedsuikerverlagende medicatie naar insuline therapie
werd beschouwd als een objectieve maat voor verslechtering van de beta-cel
functie. We vonden twee jaar na de diagnose van diabetes een verhoogd risico op
switchen naar insuline bij patiënten die antipsychotica gebruikten in vergelijking tot
niet-gebruikers van deze medicijnen; de hazard ratio (HR, een soort relatief risico)
was 2,0 (BI95%: 1,2-3,3). De daaropvolgende jaren na diagnose nam dit risico af. 
Tot slot vindt afronding van het proefschrift plaats in Hoofdstuk 8, alwaar onze
studieresultaten zijn besproken in het licht van optimalisering van diabetes
behandelingsstrategieën gebaseerd op verschillende subgroepen type 2 diabetes
patiënten die gemakkelijker geïdentificeerd kunnen worden op basis van klinische
kenmerken in plaats van de pathofysiologie. De klinische praktijk moet meer
afhankelijk zijn van de initiële repons op glucoseverlagende therapie en ernst van
diabetes bij de  diagnosestelling. Grofweg worden drie typen type 2 diabetes
patiënten onderscheiden: allereerst de primaire dieet falers, patiënten waarbij een
dieet weinig tot geen effect sorteert, vervolgens de groep waarbij een dieet alleen
toereikend is voor een goede glykemische controle en tenslotte een tussenliggende
groep bestaande uit ‘normale’ type 2 diabeten. Bovendien hebben we het belang
van validatie van de UDES database benadrukt met betrekking tot  toekomstige
onderzoeksdoeleinden.
Concluderend laten de in dit proefschrift gepresenteerde studies zien dat het
combineren van gegevens die routinematig worden verzameld in de klinische
praktijk meer inzicht kan geven in de behandeling van type 2 diabetes. Het is
belangrijk dat artsen behandelingsdoelen nastreven die redelijkerwijs haalbaar zijn
voor de individuele patiënt, waarbij de nadruk ligt op het in de pas lopen met de
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(progressieve) ziekte en de noodzaak tot het constant herbeoordelen van de
diabeet, samengaand met geschikte therapeutische aanpassingen.
De juiste farmacotherapie van type 2 diabetes mellitus is een gecompliceerde taak
voor behandelaars, opvolgende stappen in de behandeling van glykemische
controle kunnen soms gedeeltelijk worden gebaseerd op gegevens omtrent de
medicatiehistorie (bijvoorbeeld het effect van eerder gebruikte medicatie).
Samenwerking tussen artsen, apothekers en de diabeet zelf is daarom zeer
belangrijk.
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- “Proefschrift? Wanneer verschijnt dan het èchte?”
- “Promoveren, ja, dat willen we allemaal wel…!”
Dergelijke repliek ontving ik regelmatig op een willekeurig verjaardagsfeestje
tijdens een poging mijn dagelijkse bezigheden als arts-onderzoeker bondig uiteen te
zetten. Ik kan zeggen, het stimuleert je relativeringsvermogen met betrekking tot
de importantie van je onderzoek zeker! Toch is met de afronding van dit
promotietraject voor mij een belangrijke mijlpaal bereikt en wil ik van de
gelegenheid gebruik maken een aantal personen in het bijzonder te bedanken voor
hun steun en begeleiding de afgelopen jaren.
Aan de totstandkoming van dit proefschrift hebben velen een bijdrage geleverd.
Allereerst bedank ik mijn co-promotoren en promotoren.
Het UDES Project, een samenwerkingsverband tussen de disciplinegroep
Farmacoepidemiologie en Farmacotherapie van de faculteit Farmacie en het Julius
Centrum, was een leerzame en leuke ervaring. De interactie tussen beide
disciplines, farmacie en geneeskunde, werkte zeker symbiotisch en krijgt hopelijk
een toekomstig vervolg.
Dr. R.P. Stolk, beste Ronald, bedankt voor je leerzame commentaren en levendige
discussies aangaande de studies beschreven in dit proefschrift. Je enthousiasme en
bemoedigende woorden werkten zeker inspirerend. Ik vind het ook bijzonder
eervol dat jij vandaag speciaal voor mij hier naartoe komt gevlogen. Dank je!
Prof. dr. D.E. Grobbee, beste Rick, hartelijk dank voor je doortastende begeleiding
en altijd zeer doelgerichte bijdragen aan mijn onderzoek. Ik heb veel geleerd van je
methodologische en epidemiologische inzichten.
Dr. O.H. Klungel, beste Olaf, jouw farmaco-epidemiologische ervaring heeft een
belangrijke invloed gehad op de uiteindelijke kwaliteit van mijn ‘boekje’, mede
dankzij jouw snelle commentaren op de manuscripten is de afronding tijdig gelukt.
Mijn oprechte dank hiervoor! 
Prof. dr. H.G.M. Leufkens, beste Bert, jouw vertrouwen, bevlogenheid en heldere
kijk aangaande dit onderzoek zijn altijd een extra motivatie geweest, bedankt!
In het bijzonder wil ik Joëlle Erkens bedanken, de ‘at random’ match van een
Limbo en een Fries werkte uitstekend! Het was erg fijn om niet alleen diverse
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promotiefrustaties, dataworstelingen en logistieke stress te kunnen bespreken maar
ook andere interessante zaken met je te delen. Je humor, oprechte interesse en
nuchterheid heb ik altijd erg gewaardeerd. Lieve doctor Joëlle, vandaag zijn de
rollen omgedraaid en sta je aan mijn zijde, ik voel me vereerd!
Dr. R.M.C. Herings, beste Ron, als medebedenker stond jij aan de wieg van het
UDES Project. Ik wil je graag bedanken voor de prettige samenwerking.
De leden van de beoordelingscommisie, prof. dr. L.M. Bouter, prof. dr. R.S. Kahn,
prof. dr. G.E.H.M. Rutten, prof. dr. J.B.L. Hoekstra en prof. dr. A.F.A.M.
Schobben bedank ik voor het kritisch lezen van het manuscript en de nuttige
commentaren.
De huisartsen en apothekers uit Ede en Almere ben ik veel dank verschuldigd
aangezien zij hun gegevens beschikbaar hebben gesteld voor het UDES onderzoek.
Met name wil ik Martine de Bruyne en Christian Daniels bedanken voor de
tijdrovende data-extracties. Beste Martine, jij hebt een bijzondere bijdrage geleverd
aan de ‘doorstart’ van mijn onderzoek, dankzij jouw hulp en doortastendheid
leerde ik snel de eerste kneepjes van het epidemiologisch onderzoek. Tevens wil ik
de huisartsen Ernst Bouman en Berend Terluin bedanken voor hun inzet en
interesse. Het PHARMO Instituut wil ik bedanken voor het leveren van data voor
een aantal studies beschreven in dit proefschrift.
Drs. D. Cohen, psychiater, ben ik dank verschuldigd voor zijn onmisbare bijdrage
aan het artikel over het verband tussen diabetes en het gebruik van antipsychotica.
Beste Dan, mede vanwege jouw inzichten en ervaring in de psychiatrie raakte mijn
nieuwsgierigheid geprikkeld en ben ik vol enthousiasme in de literatuur over
‘tardieve dyskinesie’ en het ‘extrapyramidaal syndroom’ gedoken, een leuk zijpad!
Dr. E.R. Heerdink, farmaco-epidemioloog, gaf waardevol commentaar op het
‘refill compliance’ onderzoek (hoofdstuk 6). Beste Rob, dankzij jou ben ik nu op de
hoogte van alle ins en outs van therapietrouw-onderzoek met behulp van
apotheekgegevens.
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Prof. dr. G.E.H.M. Rutten, beste Guy, als mede-auteur van maar liefst drie
hoofdstukken uit dit proefschrift heb je me ingewijd in de huisartsgeneeskunde in
het algemeen en de diabeteszorg in het bijzonder. Je grondige commentaar en
opbouwende kritiek waren zeer leerzaam. Mijn dank!
Alle collegae van het Julius Centrum en met name de promovendi, wil ik bedanken
voor de gezellige tijd en de inspirerende werkomgeving. Daarnaast dank ik de JC
Helpdesk voor alle troubleshooting tijdens computercrashes en andere
‘onoplosbare’ problemen.
Lieve Irene, je bent voor mij veel meer dan een leuke kamergenoot. Ik bewonder je
oprechte betrokkenheid en interesse. Gelukkig konden we af en toe samen heerlijk
relativeren en de werkelijk belangrijke dingen des levens bespreken. Succes met
jouw laatste loodjes, ik mis je nu al!
Heini Meegdes, als Ronalds rechterhand was je voor mij onmisbaar! Met jouw
directheid en logistieke doortastendheid was je af en toe een rots in de branding.
Bedankt voor al je hulp, belangstelling en de gezellige momenten tijdens
congressen.
Daisy, Marlies, Mariëlle, Francine, Irene, Lisette en Joëlle, dankzij jullie werd de
NIHES opleiding in Rotterdam (bijna) leuk!
Daarnaast wil ik uiteraard alle Epithera collega, met name de promovendi,
bedanken voor de gezellige tijd. Dames van N803, Aukje en Anke Hilse, ook al
hebben jullie Joëlle laten ontsnappen aan het trouw- en babyvirus, het was altijd
leuk om weer eens langs te komen in het Wentgebouw. Gert Dekker, mijn
bijzondere dank voor je intensieve databasebewerking van de UDES gegevens, bij
problemen stond je altijd voor ons klaar! Ineke, Addy en Suzanne, bedankt voor
alle klusjes en de onderhoudende emails.
Mijn vrienden en familie wil ik bedanken voor de nodige afleiding,
hartverwarmende belangstelling en het begrip dat ik de laatste maanden iets minder
sociaal ben geweest.
Lieve ‘carpe noctem’ vriendinnetjes, Jeltsje, Kjille, Wietske en Edna. Ook al
plukken we tegenwoordig zeer zelden de nacht, mijn dank voor jullie gezelligheid
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en vriendschap door zovele jaren heen. Lieve Jel, ik vind het geweldig dat jij
vandaag naast me wilt staan!
Lieve Knickerbocker vriendjes en vriendinnetjes, in het bijzonder Linda,
Margreeth, Hillie, Esther, Ineke, Kuna en Leonie: bedankt voor alle mooie
momenten en onvergetelijke derde helften die we met z’n allen hebben beleefd! De
hoogste tijd voor een volgend reunietje denk ik zo. Utrecht?
De Groningse enclave bij Hercules zorgde bovenal voor de nodige ontspanning
door inspanning; na weer een dag promotieperikelen mijn frustraties botvieren op
de plofbal, heerlijk! Brenda, Marije, Sylvia, Afina, Marianne, Margriet, Ellen,
Mariëlle, Judith, Yvonne en nu ook Janke en Alie: ik geniet van ons team en ben
dankbaar dat we zoveel lief en leed (en sigaretten) met elkaar delen. Ik beloof bij
deze plechtig dat ik zal plaatsnemen in de eerstvolgende weekend-organisatie
commissie.
Daarnaast wil ik alle andere Herculienen en Herculanen bedanken voor de
gezelligheid op en rondom de velden.
Lieve Saskia, bedankt voor al je warme interesse, betrokkenheid en de onmisbare
gezelligheid in zowel Groningen, Alanya, Emmeloord en Hengelo, als nu in
Utrecht en Scheveningen. Biertje?
Lieve Paul, je bent bijzonder bijzonder. Dank je voor alle steun en liefde de
afgelopen jaren.
Lieve Erik (en Hanneke natuurlijk!), Patrick en Frank: hopelijk zijn jullie vandaag
een beetje trots op jullie ‘grote’ zus, ik dank jullie voor het geloof in mijn kunnen,
de opbeurende woorden en de vele leuke momenten! Dankzij jullie ben ik nu
eindelijk mobiel, emotioneel intelligent in de praktijk en tevens verslaafd aan Harry
Potter. Lieve papa en mama, mede dankzij jullie onvoorwaardelijke steun en liefde
is het me gelukt te blijven geloven in een goede afloop en deze promotie succesvol
af te ronden. Jullie vormen de basis van een altijd warm nest waar ik me steeds
welkom voel. 
Dank jullie wel!
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